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The induction of CD8+ cytotoxic T lymphocytes (CTL) is vital in the immune response to tumour 
growth, and the presence of tumour-infiltrating CTL correlates with positive prognoses. 
Immunotherapies aim to either induce potent anti-tumour immune responses through 
vaccination, or to increase the numbers of tumour-specific CTL in patients and/or strengthen 
their effector functions against tumours. However, within the tumour microenvironment (TME) 
many immunosuppressive mechanisms operate to prevent cytotoxic activity amongst CD8+ 
tumour-infiltrating T lymphocytes (TIL).  Previous studies have shown that loss of CTL function 
within the TME is associated with the influx of large numbers of FoxP3+CD4+ regulatory T cells 
expressing ectoenzymes CD39 and CD73 that catalyse stepwise adenosine production.  Other 
studies also showed that there is an upregulation in the expression of coinhibitory receptors 
(CIRs) amongst CD8+ TIL compared with CTL. We hypothesised that production of 
immunosuppressive adenosine may also contribute to CTL effector function loss through 
upregulation of CIRs, thus promoting continued tumour growth. Studies detailed in this thesis 
were carried out in order to identify changes in the expression patterns of the CIRs PD1, TIM3, 
TIGIT and LAG3 and in CTL proliferation amongst tumour-specific CD8+ T cells in the presence 
of 5′-(N-Ethylcarboxamido) adenosine (NECA), an adenosine receptor agonist; and to test the 
ability of a novel vaccine strategy using scaffold proteins called Self-Assembling peptide caGEs 
(SAGE) to deliver tumour-specific peptides to stimulate CD8+ T cell proliferation in vivo. The 
data show that NECA did not affect expression patterns of PD1, TIM3, TIGIT and LAG3 during 
CTL priming in vitro.  However, we do show that SAGE constructs are capable of driving strong 
proliferative responses of CTLs in vivo. These findings provide further insight into the 
immunosuppressive mechanisms within the TME as well the immunotherapeutic potential of 
using novel SAGE-conjugated peptides to stimulate anti-tumour CTL responses in vivo.   
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Chapter 1 - Introduction 
1.1 T Cell Lymphocytes  
T lymphocytes play an essential role in the prevention and elimination of cancer by attacking 
malignant cells to clear these from the body. Immature thymocytes are generated from 
progenitor cells in the thymus. By undergoing positive selection, double positive cells 
(CD4+/CD8+) with the ability to react with major histocompatibility complex (MHC I) molecules 
are furthered to differentiate into single positive CD8+ T cells. Following positive selection, these 
cells continue through negative selection. Thymocytes that bind ‘self’ MHC peptides undergo 
apoptosis to prevent the accumulation of self-reactive T cells and provide central tolerance. 
Cells that did not undergo apoptosis leave the thymus and migrate to peripheral lymphoid 
tissues to mature (1). 
Cytotoxic T lymphocytes (CTL) are primed when naïve CD8+ T cells encounter an antigen-
presenting cell (APC) presenting specific tumour antigens via MHC Class I molecules to the T 
cell receptor (TCR). In combination with co-stimulation through B7.1 and B7.2 on the APC 
surface binding CD28 on the T cell surface, CD8+ T cells are activated to become CTLs and 
thus begin proliferating as well as producing effector cytokines, such as interleukin-2 (IL-2) and 
interferon-γ (IFN-γ) (1, 2). Following activation, some activated CTL differentiate into central 
memory T cells. These migrate to secondary lymphoid tissues where they are maintained with 
little or no function. Upon subsequent exposure to the same antigen, they become highly 
functional cells with the ability to proliferate rapidly and produce a variety of cytokines. Central 
memory T cells establish a faster and stronger immune response to re-exposure of the antigen, 
providing last-longing immunity (3, 4).  
Dendritic cells (DC) which are considered professional APCs may also internalise and present 
exogenous, rather than endogenous, antigens via MHC I to the CD8+ T cell TCR. Other APCs 
have also been observed to cross-present, however it is most commonly observed with DCs 
(5). Cross-presentation is crucial during infections as APCs can elicit cytotoxic responses from 
CD8+ T cells without being affected themselves. Internalised peptides are processed by either 
the cytosolic or the vacuolar pathway. When entered into the cytosolic pathway, peptides are 
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degraded by the proteasome in the cell cytosol, whilst in the vacuolar pathway the processing 
occurs by proteolysis from lysosomes (6). 
Activated anti-tumour CTLs travel to the site of the tumour to infiltrate it and attempt to eradicate 
the cancer cells, as shown in Figure 1.1. CTLs eradicate target cells primarily through the 
release of cytolytic granules, but also via the Fas pathway. These granules contain perforin 
which forms pores in the target cell’s membrane. Additionally, Tumour-necrosis factor and IFN-
γ are of cytotoxic nature when produced by activated CTLs in the proximity of targets. Once 
activated, CD8+ T cells also upregulate the expression of Fas ligand on their surface; once Fas 
receptors on target cells are engaged by the ligand, the apoptotic pathway is triggered (7, 8). 
However, despite the specific priming and activation of CTLs for anti-tumour activity, clearance 
of established tumours by the immune system is rare. Further, tumour-specific CTLs that show 
Figure 1.1 - T Cell Activation and Migration 
Naïve CD8+ T cells are activated in secondary lymphoid tissues, such as the lymph node, and after 
presentation of tumour antigen by antigen-presenting cells (typically dendritic cells) in combination with 
costimulatory signals, they differentiate into CTL effector cells. Subsequently CTL enter circulation and, with 
the help of chemokines, travel to the tumour site to infiltrate its stroma. TCR on the T cells allows recognition 
of the target cells, triggering cytotoxic killing mechanisms. This leads to cell death of cancer cells, debris of 
which is in turn picked up by antigen-presenting cells that travel to nearby lymph nodes to present it. 
(Adapted from Chen et al, 2013 (75)) 
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effective tumour killing ability in vitro undertake no such activity in the tumour and are tumour-
tolerant in vivo (9). 
1.2 Immune Evasion by Tumours 
Cancer is the abnormal and uncontrollable growth of cells due to DNA damage from 
environmental and/or genetic causes. This malignant growth generally results in tumours and 
has the potential to metastasise to other tissues via the blood or lymphatic system. In the present 
age, more than 360 000 new cancer cases occur in the UK yearly and 1 out of 2 people born 
after 1960 will develop a form of cancer (10). Chemotherapy, radiation therapy and sometimes 
surgery are the traditional methods of treatment for cancer and although these treatments have 
helped to reduce the number of cancer deaths by providing means of intervention, they are still 
far from ideal. In chemotherapy patients are administered medication, such as Tamoxifen or 
Imatinib, which target tumour proliferation. Unfortunately, these drugs also affect healthy cells 
with high cell division, such as hair cells, skin cells and cells of the gastrointestinal tract, resulting 
in unfavourable side effects such as nausea, vomiting, hair loss and fatigue (11, 12). 
Radiotherapy uses radiation to stop the proliferation of tumour cells. Due to the difficulty in 
targeting the radiation to only the tumour cells, healthy surrounding cells are damaged 
collaterally. This damage results in treatment-related side effects including headaches, 
immunocompromise, subsequent infections and fatigue (13, 14). The low specificity as well as 
the physical and mental toll on cancer patients highlights the need to develop more effective 
and non-invasive treatment options. Immunotherapy which is based on utilising the host’s own 
immune system has been actively researched in recent years and provides a very appealing 
alternative.  
As normal cells undergo the transformation into cancer cells, they can develop neo-antigens 
which the immune system may recognise and react against. But often tumours avoid eradication 
by the immune system through various means, such as local immune evasion, disrupting T cell 
signalling and prompting immune tolerance (15, 16). For example, the loss of MHC class I 
expression on tumour cells prevents their recognition by anti-tumour CTLs (17), and although 
this reduced expression makes the cancer cells favourable targets for natural killer (NK) cells, 
downregulation of NK molecules as well as reduced activity of NK cells can often be observed 
in cancer patients (18, 19). 
Immunoediting refers to the process in which the anti-tumour immune response towards 
malignant cells not only prevents, but also inadvertently promotes tumour growth. It consists of 
three phases, which are illustrated in Figure 1.2; and it explains the underlying processes of 
tumour growth as well as evasion of immune responses (20, 21). 
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In the initial Elimination phase, immunosurveillance occurs during which innate effector cells 
such as natural killer cells recognise malignant cells and produce IFN-γ in response.  This 
results in inhibition of further proliferation of the cancer cells and the subsequent the production 
of chemokines such as CXCL9 and CXCL10, recruiting DCs and other immune cells to the site. 
Subsequently also antigen-specific CD4+ T cells and CD8+ T cells arrive to eradicate the 
malignant cells. Tumour cells with reduced immunogenicity however can escape this process 
(20-22). 
During the next phase, Equilibrium, cancer cells that avoided killing during immunosurveillance 
are selected for growth by the tumour. As immune cells recognise certain tumour neoantigens 
during immunosurveillance, this provides selection pressure for the tumour cells to not be 
recognised. This phase can last several years as different mutations may occur in the cells (22, 
23). 
Escape is the final phase of immunoediting. The selected-for cancer cells now continuously 
divide uncontrollably, whilst being undetected or unsusceptible to the host’s immune system 
(20, 23). 
Figure 1.2 - The Phases of Immunoediting 
Immunosurveillance detects cells in (a) and eradicates them in response. (b) shows the equilibrium stage, 
where the immune system inadvertently selects and supports mutated tumour cells that manage to not be 
eliminated. This process results in (c), where different variants of the tumour cells have generated and 
grown uncontrollably, undetectable by the immune system. 
Blue represents different mutated tumour cells, red: tumour cells undergoing proliferation, grey: non-
transformed neighbouring cells in the stroma, black flashes: cytotoxic activity against tumour cells and small 
blue circles are cytokines.     (Adapted from Dunn et al, 2002 (23)) 
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1.3 Immunosuppression in the TME 
The tumour microenvironment (TME) of solid tumours is highly immunosuppressive and 
contributes strongly to the lack of immune response against the tumour, and thus hinders its 
eradication. Many tumours continue to grow regardless of the presence of primed anti-tumour  
infiltrating T lymphocytes (TIL) within tumour stroma (24). Often the rapid growth of cancer cells 
exceeds the rate of angiogenesis, which can cause a lack of oxygen and nutrients to 
surrounding healthy tissues which, in turn, creates areas of severe hypoxia and necrosis of the 
surrounding tissues (25). 
Contributing to this immunosuppressive environment are regulatory T (Treg) cells, whose normal 
function is, amongst other things, to suppress autoreactive T cells to prevent autoimmunity. 
Tumours have been shown to express specific chemokines, such as CCL22, to attract Treg cells 
to the tumour site (26). The support of tumour growth by the presence of Treg cells is highlighted 
when Treg cells were suppressed and clearance of tumours as well as increased efficacy of 
immunotherapies were observed (27, 28). Additionally, the large number of Treg cells present in 
the TME contribute to high levels of anti-inflammatory molecules. The production of tumour 
necrosis factor (TNF) by other immune cells present also encourages growth of cancer cells 
(29). 
Due to the cytotoxicity of CTLs, it is important to control their activity to prevent excessive 
cytotoxic action. This may be done via coinhibitory receptors (CIRs) which exist to regulate T 
cell activity. However, engagement of CIRs expressed on CTLs that are primed against tumour-
specific antigens suppresses their anti-tumour functions and can cause immune tolerance 
towards the tumour (24). CIR expression is highest on T cells found in the TME, followed by 
cells in normal tissue. T cells in peripheral blood display the lowest levels of inhibitory molecules 
(24). This strongly indicates that the TME induces and maintains the expression of CIRs on 
CTLs and thus inhibits their effector functions. 
In response to persistent activation in cases of chronic infection or uncontrolled tumour growth, 
T cell effector functions are reduced or lost (3, 30). This state is called T cell exhaustion. T cell 
dysfunction has sprung from the importance of regulating T cell activity to reduce excessive 
immunopathology (30). Exhaustion varies from T cell anergy in that anergic T cells enter this 
state due to lack of costimulatory signals during activation and thus do not complete 
differentiation into functional effectors, triggering a hyporesponsive state (3, 31). Exhausted T 
cells on the other hand are competent effector cells initially but then progressively lose function 
(3).  
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Typical characteristics of functionally exhausted T cells are their lack of ability to proliferate (3) 
and limited capacity to produce effector cytokines (24). T cell exhaustion starts with initial loss 
of ability to produce IL-2, perform cytolytic activity and proliferate. This is followed by an inability 
to produce other cytokines like IFN-γ (32, 33). This inability to perform effector functions can be 
reversed during earlier stages of exhaustion, however as the exhaustion progresses the 
dysfunction becomes more permanent (3). 
1.3.1 Adenosine 
The rapid growth of the tumour creates unfavourable conditions for the survival of normal cells. 
Under extreme hypoxic conditions, adenosine production in the extracellular matrix is promoted 
due to high levels of anaerobic glycolysis and the Warburg effect (where cancer cells metabolise 
using aerobic glycolysis rather than the more efficient oxidative phosphorylation pathway) (34). 
Under normal conditions adenosine, a purine nucleoside, is immunosuppressive and functions 
at relatively low concentrations comparable across different tissues (35). It plays an important 
part in homeostatic processes, such as vasodilation, mast cell activation and immunomodulation 
(36). In tumours, enzymes involved in deamination and adenosine phosphorylation are found in 
abundance. The presence of these enzymes therefore suggests that they may be potentially 
manipulated to control the adenosine concentration in the TME (37).  
Anaerobic glycolysis in combination with the Warburg effect results in the abundance of AMP 
as well as increased CD73 expression by tumour cells (38). 5’nucleotidase, also known as 
CD73, is an ectoenzyme which catalyses the breakdown of AMP into adenosine (34, 39, 40). 
5’nucleotidase further contributes to increased adenosine concentrations through the 
dephosphorylation of ATP into adenosine with the help of CD39 (another ectoenzyme) (41) as 
well as breakdown of extracellular adenine nucleotides (37, 40, 42, 43). Adenosine is 
Figure 1.3 - The Adenosine Cycle 
ATP is broken down into ADP by CD39 on the cell 
surface. ADP may also be further broken down by 
CD39 to AMP. AMP is then broken down to 
Adenosine by ectoenzyme 5’nucleotidase (CD73). 
Adenosine binds to adenosine receptors to activate 
them or is broken down by Adenosine Deaminase 
(ADA) into Inosine extracellularly. Alternatively, 
equilibrative nucleoside transporters (ENTs) can 
transport adenosine into the cell, where it is 
phosphorylated by adenosine kinase (AK) to AMP. 
(Adapted from Bowser et al, 2018 (44)) 
Chapter 1 - Introduction 
7 
 
metabolised by adenosine deaminase (ADA) and adenosine kinase, as displayed in Figure 1.3 
(36, 40, 44). 
Adenosine receptors comprise A1, A2A, A2B and the A3 receptors (45). These are 
metabotropic, G-protein-coupled receptors that work downstream via adenylyl cyclase (35, 46). 
They are further categorised into high-affinity (A1 and A2A), low affinity (A2B) and low 
abundance (A3) receptors (40, 47). Adenosine A2A receptor (A2AR) is most commonly found 
on immune cells and is considered a T cell surface CIR due to its inhibitory effect on T cells 
when bound by adenosine (34). It is considered a high affinity adenosine receptor due to its 
adenosine-binding at low concentrations (48). A2AR and A2B adenosine receptors (A2AB) are 
known to dampen immune effector functions as well as increase the prevalence and activity of 
immunosuppressive cell subsets when activated (41). Increased adenosine concentration leads 
to the upregulation of A2AR on the CTL surface, increasing their susceptibility to inhibition (34). 
Concentrations of adenosine around tumours are between 10- and 20-fold higher than when 
compared to subcutaneous measurements in the same location (37). This elevation of 
adenosine in the TME impedes anti-tumour immunity (49). Adenosine influences cytotoxic T cell 
activation and effector functions by engaging the A2AR receptor on the T cell surface and thus 
interfering with their recognition of and adhesion to target tumour cells (37, 43). Adenosine has 
also been shown to inhibit the exocytosis of cytotoxic granules by natural killer cells as well as 
contributing to multi-drug resistance in glioblastoma treatment (25, 37). CD8+ T cells are more 
susceptible to the immunosuppressive effect of adenosine due to the relatively low ADA activity 
in CTLs which is found alongside CD26 on the T cell surface (50). CD26 is a T cell activation 
antigen which binds to ADA as it is released and mediates the effects of adenosine on the cell 
(51). Adenosine further inhibits anti-tumour CTL function in a variety of ways. When T cells 
undergo activation in the presence of adenosine, CD25 (a high-affinity IL-2 receptor) expression 
is lower than on cells that activated in the absence of adenosine. In addition, adenosine inhibits 
Fas ligand expression and decreases granzyme B expression of CTLs which interferes with 
their cytotoxic activity (43). Apart from this, adenosine has been shown to increase transcription 
and expression of 5’nucleotidase as well as inhibit adenosine kinase activity, creating an 
environment favouring adenosine synthesis (37, 43, 52). Under hypoxic conditions adenosine 
kinase has been shown to be inhibited which also further contributes to elevated adenosine 
concentrations in the TME (43). 
 
1.3.2 Coinhibitory Receptors 
Due to the wide range of immunosuppressive factors within the TME, CTLs are pushed towards 
an exhausted phenotype, impairing their anti-tumour activity and thus allowing the tumour to 
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continue to grow without clearance. Amongst their lack of ability to perform effector functions, 
exhausted CD8+ T cells are also characterised by the increased expression of CIRs on their 
surface (30, 32). These receptors are expressed transiently on the cell surface after CTL 
activation and when engaged with their ligands, CIRs inhibit CTL functions (53). It is important 
to note that whilst high CIR expression is associated with dysfunction, transient expression of 
CIRs is expected for activated cells to provide a means of controlling their activity. A lack of 
control of the CD8+ T cell cytotoxic mechanisms leads to excessive cytotoxic activity, the 
damaging consequences of which are demonstrated in autoimmune diseases such as multiple 
sclerosis (54). However, this regulatory mechanism has been utilized by tumours to enable them 
to evade immune clearance by the immunosuppressive factors in the TME leading to 
upregulation of CIRs on anti-tumour CTLs (2, 46).  
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), is the first CIR to be identified on T cells. 
It is highly homologous to CD28 and bind B7 molecules with high affinity. When bound to its 
ligands, CTLA4 inhibits T cell proliferation and IL-2 production (53, 55).  
PD1 
Programmed cell death-1 (PD1) receptor is also expressed by CTLs. It is part of the CD28 family 
and is considered a hallmark for both T cell activation and exhaustion (56). PD1 is expressed 
on a variety of other cells, such as natural killer cells, B cells and activated monocytes, and is 
activated when bound by its ligands PDL1 and PDL2 (56-58). PDL2 expression is much more 
limited than that of PDL1. PDL1 is found on several immune cells, for example macrophages, 
DCs, B and T cells, as well as on tumour cells (58, 59). PDL1 is largely expressed on different 
solid tumours, such as breast, colon, liver, neck. High levels of PDL1 expression contribute to 
the immunosuppressive environment of tumours and acts in synergy with other factors to inhibit 
CTL function (58). For example, PDL1 is able to interact with B7.1, sending inhibitory responses 
to the T cells in a bidirectional manner due to the expression of both on immune cells like DCs, 
macrophages, B cells and T cells (60). Additionally, the IFN-γ production by T cells causes 
increased PDL1 expression on tumour cell surface, which upregulates and binds PD1 on the T 
cell surface creating an immunosuppressive loop (61). Once activated, PD1 protects T cells 
from overstimulation by acting via PI3 kinases and inhibiting the expression of transcription 
factors for effector functions, such as GATA3 and Tbet (15, 62, 63). It also significantly affects 
production of effector cytokines, e.g. IFN-γ and TNFα (56, 58). TILs have been shown to express 
higher levels of PD1 on their surface than T cells found in the peripheral blood and normal 
tissues, indicating the upregulation of this CIR by the tumour in the TME (24).  




PD1 has been shown to very often be co-expressed with T-cell immunoglobulin and mucin-
domain molecule 3 (TIM3). When bound by its ligands, such as Galectin 9, TIM3 sends apoptotic 
signals to the cell, initiating its death (64). However, cell death appears to be triggered only at 
high levels of TIM3 engagement; when TIM3 is bound at low levels, this seems to convey 
inhibitory signals inciting CTLs into a dysfunctional state rather than cell death which explains 
how exhausted T cells persist in chronic conditions (64).  
TIM3 upregulation is thought to hallmark extensively exhausted cells (32). Blockade of TIM3 
has been shown to restore the proliferative and cytokine production ability of TIM3+ CD8+ T 
cells (64). Further, TIM3+ cells have been observed to display the highest levels of co-
expression of other CIRs than the co-expression seen with other checkpoints. This highlights 
the role of TIM3 as a marker for CD8+ T cell exhaustion (65). In renal carcinoma and human 
melanoma, the expression of both PD1 and TIM3 together on CTLs has been correlated with a 
poor prognosis of said cancers (66, 67). PD1+TIM3+ CTLs found in tumours have been shown 
to display the most severe effector dysfunction than when compared to other combinations of 
CIR expression (64). TIM3 is also abundantly found on Treg cells, where cells that expressed 
PD1 alongside TIM3 are highly immunosuppressive, further highlighting the inhibitory nature of 
this CIR combination (68). 
LAG3 
CIR lymphocyte activation-gene 3 (LAG3) inhibits T cell effector functions as well as cell 
expansion by interfering with downstream TCR signalling (33, 66, 69). It is commonly found on 
CD4+ and CD8+ T cells and due to its progressive expression on dysfunctional TILs has also 
been associated with CD8+ T cell exhaustion (64, 66, 70). High surface levels of LAG3 on the 
surface of CTLs have been correlated with a poor outcome in renal cell carcinomas (66). LAG3 
localises next to the CD3-TCR complex on the T cell surface and is activated when bound by 
MHC II molecules on APCs (70). Once activated, it negatively regulates T cell activity and 
inhibits signal transduction via the TCR (71). 
TIGIT 
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) has been 
strongly linked to immunosuppression. When bound by its ligands CD155 and CD112, it inhibits 
DC maturation and induces secretion of the immunoinhibitory IL-10 of immature DCs (72). 
CD155 binds TIGIT at high affinity, whilst CD112 does so with low affinity. Both molecules are 
involved in anti-tumour activity of T and natural killer cells (73) and are found on APCs as well 
as tumour cells, such as melanoma cells  (72). TIGIT is expressed by Treg cells, activated T 
cells and natural killer cells. Especially its immunoregulatory role in Treg activity has been 
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highlighted by TIGITHIGH Treg cells being highly immunosuppressive. In addition to this, CTLs 
with high surface levels of TIGIT have been shown to be incapable of performing effector 
functions (74). Further, upregulation of TIGIT has been correlated with expression of PD1 on 
TILs (72). 
Targeting CIRs in tumour therapies is an active area of research. Being able to interfere with 
the inhibition of anti-tumour CTLs would allow restoration of the immune system’s defences and 
thus clearance of the malignant cells.  
1.4 Immunotherapies 
Immunotherapies provide a novel route to target malignancies in cancer treatment. The 
invasiveness and side effect profiles of traditional therapies are not applicable to treatments 
based on the host’s own immune system. Cancer immunotherapies allow specific targeting of 
therapies, which further provide the potential of long-lasting immunity against cancer (75). A 
wide range of routes are investigated to restore and utilise endogenous anti-tumour activity. For 
example, using adoptive cellular therapy in which CD4+ T cells and CTLs are removed from the 
patient’s blood or tumour, then expanded ex vivo to increase their numbers and returned to the 
patient in combination with different cytokines to fight the tumour. This is done in an attempt to 
counter the immunosuppression exerted by the tumour on immune cells and has been shown 
to elicit high response rates (49% to 72%) and longevity of tumour regression (76, 77). However, 
adoptive cellular therapy has several problems. For example, the depletion of T cells from the 
body leaves it susceptible to infections, especially when paired with radiotherapy as is often 
conventional in cancer treatment. The emergence of synthetic biology has allowed a different 
route to improving anti-tumour immunity by providing the ability to engineer CTLs. Central 
tolerance prevents autoimmunity of CD8+ T cells against healthy cells, however this mechanism 
also means that CTLs are often tolerised against tumour antigens. Furthermore, the few anti-
tumour CTLs that do manage to escape central tolerance are not strongly activated against 
tumour-antigens and exhibit low-affinity TCRs. The transfer of TCR α and β chains specific for 
tumour-antigens aims to help effectively target CTLs to tumour tissue. This method allows for 
the engineering of the TCR to exhibit higher affinity for antigens (78).  
Chimeric antigen receptors (CAR) aim to overcome central tolerance with a different approach. 
CARs are made by fusing the variable domain of immunoglobulin molecules to the constant 
domain of TCRs (including their intracellular signalling domains) and recognise target proteins 
on the cell surface without being dependent on display of tumour antigens via MHC molecules 
(79). Due to the much higher affinity of antibodies than TCRs for their targets, this provides anti-
tumour CTLs possessing CARs with the potential to overcome central tolerance (76, 78). These 
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methods of T cell engineering have shown tumour regression in several cancers like melanoma 
and sarcoma (80). 
A common aim of immunotherapies is to increase the number and strengthen the cytotoxic 
functions of endogenous CTLs present in the patient, since high quantities of TILs have been 
associated with good prognoses in several cancers, such as colorectal, renal, breast, 
oesophageal and non-small-cell lung cancer (81-85). This highlights the importance of therapies 
to establish strong and proliferative tumour-specific CTL responses. DC-based therapies target 
the professional APCs to improve their presentation of antigen to CD8+ T cells via MHC class I 
molecules and to ultimately initiate CTL proliferation. This may be done by loading patients’ DCs 
with tumour antigens ex vivo and returning them back to the patient (86). Ex vivo culturing of 
DCs has shown clinical safety and lasting responses (87).  
However, it is important to note that adoptive transfer of CTLs or their activation do not always 
suffice to eradicate the tumour, due to the tolerance to cancer antigens and the 
immunosuppression experienced by CTLs that occurs in the TME. 
1.4.1 Targeting Immunosuppression 
Another route to improve patients’ own immune reaction against cancer cells is to target the 
immunosuppressive tactics employed by the tumour to prevent CTLs from performing their 
cytotoxic functions. As mentioned, high levels of extracellular adenosine can greatly contribute 
to the inhibitory nature of the TME. Therapies aimed at targeting adenosine are focussed on 
one of two routes, to either manipulate adenosine synthesis or adenosine signalling. This is 
mostly attempted using inhibitors in the form of small molecules but can also be done using 
blocking antibodies or pharmacological mediation (88, 89). Small molecules inhibiting A2AR 
and A2BR have been shown to inhibit and prevent the metastases of CD73+ tumours (89). 
A2AR antagonists are currently being investigated clinically in Parkinson’s disease and exhibit 
great clinical safety suggesting that these agents could potentially be translated into cancer 
treatments (90).  
5’nucleotidase also presents an attractive target for anti-tumour therapies due to its role in the 
production of adenosine, angiogenesis and role as a mediator for tumour and immune cell 
migration (41). Furthermore, 5’nucleotidase is expressed highly on cancer cells and cancer-
associated fibroblasts alongside A2AR (34). Expression on tumour cells has been associated 
with increased tumour migration and invasive capability (88, 91). Thus, 5’nucleotidase carries 
great potential as a tumour biomarker to identify poor prognosis and metastases of tumours. 
However, although this aspect is highly researched, currently no fully human or humanised anti-
5’nucleotidase antibodies have been generated for therapeutic use in the clinic (41, 92).  
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1.4.2 Targeting Coinhibitory Receptors 
Studies have shown that monoclonal antibodies (mAbs), which block the signalling via CIRs, 
improve CTL functions in vitro and increase tumour killing in vivo in several animal models, 
displaying how CIR blockade can rapidly reinstate the effector functions of tumour-specific CTL 
(93-96). In clinical trials in which Iambrolizumab, a mAb that targets PD1, was given in patients 
with advanced melanoma, half of the cohort responded (102). Other trials using alternative anti-
PD1 mAbs Pembrolizumab and Nivolumab were also very promising; these blockades 
displayed clinical efficacy and durability in a variety of cancer types (63). Nivolumab has 
provided long-term immunity in patients with melanoma and has also been shown to elicit strong 
responses in patients with renal-cell and non-small-cell lung cancer  (97, 98).  Indeed, in patients 
with PDL1+ non-small-cell lung cancer patients, treatment with Pembrolizumab gave rise to 
longer time periods without tumour progression, an overall better prognosis with fewer side 
effects than patients receiving chemotherapy (99). The development of these drugs provides a 
novel and highly effective alternative treatment of melanoma and non-small-cell lung carcinoma 
and both, Pembrolizumab and Nivolumab, are now FDA-approved therapies for these cancers 
(100, 101).  
Despite this success, many patients receiving treatment with one type of CIR inhibitor do not 
always respond and many cancers have proven resilient to anti-CIR therapies (61, 63, 93, 95, 
100, 102). It can prove challenging to target therapies to dysfunctional T cells via CIRs 
specifically, since these markers are also associated with T cell activation which means these 
markers are found also on functional T cells and exhibit versatile expression profiles. Due to its 
strong association with both activation and exhaustion, especially the development of TIM3-
blockade has proven difficult (15). Furthermore, the complexity of CIR interaction also very likely 
contributes to the limited successes of CIR blockade therapies. The co-inhibitory system 
presents a variety of non-overlapping ways to achieve disruption of T cell functions and multiple 
inhibitory pathways are in existence which may cooperate to inhibit CTL effector functions. Their 
interactions are not well understood, thus blockade of one signalling pathway can cause the 
activation of different receptor signalling instead (32). The poor understanding of downstream 
mechanisms of CIRs further complicates the development of therapies against the receptors 
(32). Based on this non-redundancy of the CIR system, blocking of several CIRs at once is 
actively researched and has proven clinical efficacy. Blockade of TIGIT as well as PD1 
increased CTL expansion and effector functions as well as CTL numbers in the periphery and 
the tumour site in advanced melanoma patients (72). Concurrent therapy of Ipilimumab (an anti-
CTLA4 mAb) and Nivolumab elicited higher immune activity in melanoma patients than either 
therapy alone. The patients elicited rapid responses and moreover, the majority of patients 
displayed 80% or higher tumour regression after 12 weeks of treatment (63, 98, 103). The 
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combination of Ipilimumab and Nivolumab has also been shown to be effective in the treatment 
of non-small-cell lung carcinoma; patients with PDL1+ tumours displayed increased and durable 
response rates (104). However, the potential toxicity of combining the blockade of several CIRs 
has been questioned. As more agents are being used, more cases of immune-related adverse 
events (IRAE) have been reported than in therapies using one CIR blocker only. These included 
thyroid dysfunction, pneumonitis and dermatologic effects (63, 105, 106). In the study assessing 
the combination of Ipilimumab and Nivolumab in melanoma patients conducted by Wolchok et 
al (2013) ~50% of patients experienced IRAE from the treatment. Nonetheless, these responses 
were similar to those experienced in monotherapy alone and were generally reversible (98). 
Despite the success of multiple CIR blockade in some cancers, many patients still do not 
respond these therapies. Furthermore, several cancers have been shown to be resistant (107, 
108).  
The recent advances and successes in CIR blockade highlight the significance of their potential 
as cancer immunotherapeutic targets. Nevertheless, the variability in responses seen in patients 
also underlines the importance of investigating the expression patterns of receptors to be able 
to target them therapeutically (3). This knowledge is also crucial in terms of identification of 
biomarkers to predict the prognoses of different tumours (15). 
 
In an aim to try to increase the efficacy of immunotherapies, several approaches to improve 
tumour immunity are also being tested in tandem. For example, it was found that the 
combination of A2AR blockers as well as inhibition of CIRs showed great success (34). This co-
blockade increased CTL effector function and reduced metastases of melanoma and mammary 
tumours in mice (41). Further, the blockade of A2AR as well as low CD73 expression reduced 
expression of PD1 significantly, highlighting that targeting adenosine prior to anti-PD1 treatment 
may increase the efficacy of treatment by increasing the ratio of antibody:target (41). Based on 
the recent success of multiple CIR blockade, this route is being explored in combination with 
traditional cancer treatments like chemotherapy. The combination of Nivolumab and Ipilimumab 
with chemotherapy in the treatment of non-small-cell lung carcinoma is currently being explored 
in several Phase III clinical trials (104). These promising findings from initial trials of different 
agents highlight the importance of combining different strategies to restore efficient anti-tumour 
immunity. However, it is important to take dose-titrations of treatments into account to prevent 
IRAEs from summated immune toxicities when combining several therapies (109). 
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1.4.3 Tumour Vaccines 
Tumour vaccinations provide a different route to improving the host’s anti-tumour responses. 
Vaccination with tumour antigens or agents to better the presentation of tumour antigens in 
order to boost the anti-tumour response are amongst the most researched tumour vaccine 
methods (15). The targets of anti-cancer vaccines are highly variable. However, as mentioned, 
a highly desirable outcome is the proliferation of strongly primed anti-tumour effector CD8+ T 
cells to fight the tumour and develop memory T cells. Thus, DCs are commonly targeted to 
improve the presentation of tumour-antigen. As professional APCs these are the most efficient 
at driving strong proliferative responses of CTLs. Additionally, the delivery of the vaccination 
may be targeted into the cross-presentation pathway of DCs to elicit CD8+ T cell responses. 
Provenge, an FDA-approved vaccine, is used in the treatment of prostate cancer. By delivering 
the prostate cancer antigen prostate acid phosphatase (PAP) along with granulocyte-
macrophage colony-stimulating factor (GM-CSF; a stimulant of DCs which is essential to ensure 
their maturation), it initiates DC activation and antigen presentation, leading to the activation of 
PAP-specific CTLs. Development of Provenge has allowed increased survival of patients with 
prostate cancer (110). A different approach using DCs is the genetic engineering of cancer cells 
to express GM-CSF in GVAX vaccines. Production of GM-CSF recruits and activates APCs, 
including DCs, and encourages internalisation of the tumour cells for cross-presentation to 
CD8+ T cells (111). These therapies have shown clinical efficacy in a variety of cancers (112, 
113). 
A limitation of tumour vaccines is the difficulty in identifying tumour-specific antigens which are 
not found on healthy tissues in order to prevent side effects (114).  Melanoma is one of the few 
cancers against which effective vaccinations have been developed, due to malignant lesions 
consistently expressing certain antigens and thus enabling efficient CTL effector function in 
response to vaccination (109). The potential need for adjuvants, ensuring correct delivery to the 
target and tolerization to the delivered agent however are amongst the many other obstacles in 
the way of developing the ideal cancer vaccine (75). 
 
1.5 SAGEs 
Self-assembling peptide cages (SAGE) are synthetic, flexible networks formed by the assembly 
of short de novo coiled-coil peptides. These are formed by two complementary hubs, hub A and 
hub B. The trimeric hubs are created upon mixing of a homotrimer with either heterodimer A or 
B and the formation of disulphide bonds between them. Hub A and hub B are then mixed to 
build SAGEs, as shown in Figure 1.4. Further sequences can be added to SAGEs via their C-
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terminus. Full proteins may be encapsulated by these networks, enabling the addition of 
localising proteins (e.g. GFP) to SAGEs (115). The possibility of exchanging the components of 
SAGEs allows alteration of their physical properties, such as size and charge, and makes them 
highly customisable to encapsulate a variety of material, such as enzymes or peptides.  SAGEs 
provide an alternative method of delivering tumour vaccines and carry great potential to initiate 
desired antigen-specific responses. 
Vaccine delivery methods such as subunit vaccines (in which highly immunogenic portions of 
pathogens are used), are usually limited in terms of components that can be administered via 
e.g. liposomes. In the meantime, a recent study by Morris et al (unpublished; (116)) 
demonstrates that SAGEs are highly variable, non-toxic and immunogenic, and their modular 
nature allows interchangeability of components as well as the potential of protein attachment to 
the surface for precise targeting of a vaccine (116, 117). SAGEs also allow for the inclusion of 
several antigens together to deliver multivalent vaccines (75, 116). It has also recently been 
demonstrated that SAGEs are internalised by APCs in vitro which further highlights their 
potential as a DC-targeting agent to prime CD8+ T cells and elicit proliferative responses.  
Furthermore, the ability of SAGEs to trigger CD4+ T cell and B cell responses to specific 






Figure 1.4 - The Assembly of SAGEs 
SAGE molecules are built by the assembly of the hub A and hub B building blocks. These blocks in turn are 
made of two separate de novo peptides, a homotrimer (CC-Tri3) and a heterodimer (either CC-Di-A or CC-Di-
B). Upon mixing of the homotrimer with one of the heterodimers, they bind through disulphide bonds and 
create Hub A and Hub B. Subsequent combination of the two hubs leads to their co-assembly into hexagonal 
networks which fold to form SAGE nanoparticles. Adapted from Fletcher et al, 2013 (117) 
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Because of these characteristics, especially the ability to add molecules to their exterior, SAGEs 
could be used in a tumour vaccination setting where encapsulated material can be targeted to 
DCs and into the cross-presentation pathway, to drive strong CTL proliferation and thus 
increase the number of tumour-specific, strongly activated CTLs.  
1.6 CL4 Model 
To study the immunosuppressive characteristics of tumours as well as the immune response 
against them, our lab uses BALB/c clone 4 TCR transgenic mice.  This model was created by 
infecting B10.D2 mice with the influenza virus A/PR/8 H1N1 (PR8) and injecting isolated TCR 
cDNA from CTLs of the infected mice into fertilised mouse oocytes. Matured mice were then 
backcrossed for 5 generations to strengthen the genetic background (C57BL/6 X BALB/c) (118). 
The clone 4 (CL4) model thus expresses transgenic CL4 CD8+ T cells with TcR, composed of 
variants Vα10 and Vβ8.1, which are specific to the immunodominant Kd-restricted HA epitope 
(518IYSTVASSL526) and bind it with high affinity (119). 
Renal carcinoma (Renca) wildtype cells were generated from BALB/c mice (120). These murine 
cells were transfected using pIRES-HA plasmid which encodes the haemagglutinin (HA) gene 
from PR8 to create the Renca HA cell line which is recognised by TcR transgenic CL4 CD8+ T 
cells (120). Subcutaneous injection of RencaHA cells into BALB/c mice gives rise to solid 
carcinomas which express the HA protein and KdHA peptide complexes which can be used to 
study the properties of the TME. Adoptive transfer of naïve CL4 CD8+ T cells into RencaHA 
tumour-bearing BALB/c mice results in their activation through cross-presentation of KdHA 
epitopes by DCs within tumour-draining lymph nodes. Low avidity CD8+ T cells become 
tolerised and only a very small amount infiltrates the tumour, whilst more TILs were developed 
when high avidity CL4 CD8+ T cells were primed in the tumour-draining lymph node 
(TDLN;(121)). However, once CL4 effector CTL travel to the site of the tumour, no tumour-killing 
is undertaken and the tumour continues to grow (121). Further examination of the CL4 TIL 
revealed a loss of CTL function, including the inability to produce IFN-γ (121).  
Later studies in our lab found that in the TME expression of 5’nucleotidase and CD39 is 
increased on a variety of infiltrating cells which has the capacity to contribute to the elevated 
adenosine levels in the TME.  Most notably, high levels of 5’nucelotidase and CD39 on the 
surface of CD4+CD25+FoxP3+ Treg cells were significant, since these cells were highly 
abundant in the TME but not in TDLN (illustrated in Figure 6.1 in the Appendix). Additionally, it 
was found that co-culturing of these Treg cells with CL4 CD8+ T cells ex vivo lead to complete 
suppression of CL4 CD8+ T cell effector function, indicating that the tumour-infiltrating Treg cells 
could directly inhibit CL4 CTL function. However, the addition of an adenosine receptor 
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antagonist into this culture found significant restoration of CL4 CD8+ T cell proliferation. These 




Several factors in the TME affect anti-tumour CD8+ T cells and suppress their functions to 
promote an exhausted phenotype. We hypothesise that the upregulation of co-inhibitory 
receptors on the surface of CD8+ T cells is related to the increased concentration of adenosine 
experienced by the cells in the TME. Further, we hypothesise that the use of SAGE particles 
can improve the CD8+ T cell proliferative response by allowing cross-presentation of delivered 
peptide with MHC class I molecules.  
 
Hypothesis 1: 
Adenosine dampens the proliferative ability of CD8+ T cells in vitro 
Experimental Approach: 
i. Culture CD8+ T cells with varying concentrations of NECA in vitro and examine how 
this affected their proliferation compared to untreated cells. 
 
Hypothesis 2:  
Adenosine increases the expression of coinhibitory receptors  
on the CD8+ T cell surface in vitro 
Experimental Approach: 
i. Assess how expression of TIM3, TIGIT, LAG3 and PD1 changes in vitro as CD8+ T 
cells activate using a pulsed splenocyte reaction or anti-CD3 and anti-CD28 
monoclonal antibodies 
ii. Determine the changes in these receptors when CD8+ T cells are cultured in vitro in the 
presence of different concentrations of NECA. 
 
 




Conjugated SAGE particles can trigger CD8+ T cell activation  
and proliferation in vivo 
Experimental Approach: 
i. Test the ability of various HA peptides to prime CD8+ T cells alone in vitro 
ii. Assess the ability of conjugated peptide-SAGEs to prime CD8+ T cells in vivo  
iii. Determine whether conjugation of HA peptides to SAGE improves the CD8+ T cell 
proliferative response in vivo compared to peptides alone 
  
Chapter 2 - Materials and Methods 
19 
 
Chapter 2 - Materials and Methods 
2.1 MATERIALS 
2.1.1 Buffers 
2.1.1.1 MACS Buffer 
MACS Buffer was used for magnetic-activated cell sorting. It was prepared by adding 0.5% (w/v) 
Bovine Serum Albumin (BSA; Sigma-Aldrich, St. Louis, USA) and 2mM EDTA (Sigma-Aldrich) 
to 1x Phosphate buffered saline (PBS; Thermo Fisher Scientific, Waltham, USA). The solution 
was then filtered through a 0.45 μm filter (Sartorius Stedim Biotech, Goettingen, Germany) and 
stored at 4˚C. 
2.1.1.2 FACS Buffer 
FACS Buffer was used for cell surface staining. FACS Buffer consisted of 0.5% (w/v) BSA in 
PBS which was then filtered through a 0.45 μm filter (Sartorius Stedim Biotech) and stored at 
4˚C. 
2.1.2 Cell Culture Reagents 
2.1.2.1 Complete Medium (CM) 
CM contained RPMI 1640 with L-Glutamine (Thermo Fisher) supplemented with 10% (v/v) fetal 
bovine serum (FBS; Lot 1851515; Thermo Fisher), 50 U/ml penicillin/streptomycin (Thermo 
Fisher) and 5 x10-5 M b-Mercaptoethanol (Sigma-Aldrich). 
2.1.2.2 IL-2 Medium 
IL-2 medium was prepared in a similar manner to CM, with the addition of 0.1% (v/v) hIL-2 (NCI 
Preclinical Repository, Maryland, USA). 
2.1.3 Mice 
6 to 8-week old Thy1.1+/+ CL4+/- BALB/c TCR transgenic (CL4) mice (specific to dominant KdHA 
peptide (518IYSTVASSL526); (118)) and Thy1.2+/+ BALB/c mice were used. Mice were bred in 
specific pathogen-free conditions at the University of Bristol Animal Services Unit. All 
experiments were conducted in accord with current UK Home Office guidelines. Mice were 
culled by either cervical dislocation or exposure to gradually elevating CO2.  
2.1.4 P815 Mastocytoma Cells 
Non-adherent P815 Mastocytoma cells were purchased from ATCC (Manassas, USA). 
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2.1.5 Passaging of Renca and P815 Cells 
Adherent Renca and non-adherent P815 cells were maintained in CM.  
Adherent Renca cells were routinely passaged at 70 - 80% confluency. Tissue culture CM was 
removed and cells were washed with PBS. Following this, cells were incubated with 2 ml of 1X 
Trypsin – EDTA solution (Sigma-Aldrich) at 37˚C for 3 minutes to detach the cells. Trypsin was 
then neutralised with 5 ml of CM and cells were collected into 15 ml falcon tubes (Corning, New 
York, USA) and centrifuged at 1200 rpm for 3 minutes. Pelleted cells were then resuspended in 
CM, seeded into either new T25 or T75 cm2 tissue culture flasks at suitable split ratios and kept 
in a humidified incubator at 37˚C and 5% CO2 atmosphere. 
Passaging of non-adherent P815 cells was performed at 70 - 80% density by removing a portion 
of cells from the culture flask. The removed volume was replaced with CM for an appropriate 
seeding density and tissue culture flasks were kept in a humidified incubator at 37˚C and 5% 
CO2 atmosphere. 
2.1.6 A/PR/8/H1N1 Virus 
A/PR/8/H1N1 influenza virus was prepared in house. 
2.1.7 Antibodies for Flow Cytometry 
A range of monoclonal antibodies (mAbs) specific to murine extracellular and intracellular 
molecules were applied. All antibodies used for staining for analysis by flow cytometry were 
conjugated directly to fluorochromes. All antibodies were titrated and optimal concentrations 
(highest dilution of antibody still giving a clear separation between positive and negative 
populations) were chosen. In most cases, a stain index was also calculated to compare the 
difference between positive and negative signals. Further information of the antibodies used, 
including their staining concentrations used, can be found in the appendix (Table 6.1). In 
staining panels using several antibodies, and thus several fluorochromes, Fluorescence Minus 
One (FMO) controls were prepared. These contain all antibodies used except for one 
fluorochrome-conjugate which allows representative gating and interpretation of flow cytometric 
data. 
2.1.8 Peptides 
Peptides synthesis was performed at the University of Bristol BrisSynBio facility using a CEM 
Liberty Blue peptide synthesiser. Peptides were purified using high performance liquid 
chromatography (HPLC) and identified by MALDI-TOF mass spectrometry. Peptide purity 
(>85%) was analysed by RP–HPLC. Peptides were then freeze-dried and stored at -20˚C in 
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powder form. Just prior to use, peptides were reconstituted in PBS and concentration was 
adjusted accordingly. 
The following peptides were used and were kindly provided by Caroline Morris (School of 
Chemistry, University of Bristol): 
EPITOPE   H-IYSTVASSL-OH 
POL    H-AVGAGATAEEIYSTVASSL-OH 
LEADER   H-EKLAGFGAVGAGATAEEIYSTVASSL-OH 
Constituents of SAGE particle: 
CC-Tri3   Ac-G EIAAIKK EIAAIKC EIAAIKQ GYG-NH 
CC-Di-A   Ac-G EIAALEK ENAALEC EIAALEQ GWW-NH 
CC-Di-B   Ac-G KIAALKK KNAALKC KIAALKQ GYW-NH 
 
The self-assembling peptide cage (SAGE) particle consists of a mixture of a homotrimer (CC-
Tri3) and a heterodimer (CC-Di-A + CC-Di-B). Combination of the particles forms 
complementary hub A (CC-Tri3-CC-Di-A) and hub B (CC-Tri3-CC-Di-B) constructs which serve 
as SAGE building blocks. When mixed, association of CC-Di-B and CC-Di-A in the constructs 
leads to co-assembly of the hubs and thus the formation of the SAGE particle (117). 
Functionality is introduced into the SAGE by adding to the C-terminus of the homotrimer, in this 
case using the above POL sequence. 





Treatments described below that involved direct handling of mice were kindly performed by Dr 
Grace Edmunds and Dr David Morgan. 
2.2.1.1 Genotyping of Mice 
Blood samples from tail veins of weaned CL4 mice were stored in PBS supplemented with 
heparin to avoid clotting. Peripheral blood was stained with fluorescently-labelled mAbs against 
CD8α and Vβ8.1 to type for CL4 TCR gene expression (shown in Figure 6.2 in the Appendix). 
Erythrocytes were lysed by adding 1 ml of Ack Lysing buffer (Thermo Fisher) for 3 minutes at 
RT. Lysis was stopped by adding 10 ml CM. 
2.2.1.2 Adoptive Transfer of CL4 CD8+ Cells 
In some instances, BALB/c mice were inoculated intravenously with 3-5 x106 naïve, MACS-
purified and CTV-labelled (described below) CL4 CD8+ T cells in 100 µl PBS.  
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Mice were left for 4 or 8 days, then spleens, and in some cases lymph nodes, were collected 
for further investigation. 
2.2.1.3 Infection with Influenza for in vivo Experiments 
Treatment of mice was assigned using precautions to eliminate batch effects by numbering mice 
and randomly assigning treatments to numbers. 
Following Adoptive Transfer, mice received intraperitoneal injections to administer 
approximately 1200 HA units of influenza virus strain A/PR/8/H1N1. 
Mice were left for 3 or 7 days, then spleens were collected for further investigation. 
2.2.1.4 Inoculation with SAGE particles for in vivo Experiments 
Treatment of mice was assigned using precautions to eliminate batch effects by numbering mice 
and randomly assigning treatments to numbers. 
Following Adoptive Transfer, Self-assembling peptide cage (SAGE) particles were injected 
subcutaneously with 1 mM of peptide material in 100 µl PBS into the dorsal neck-scruff of mice. 
Peptide-only treatments were administered in an identical manner. 
Mice were left for 4 or 8 days, then spleens were collected for further investigation. 
2.2.2 Counting Cells using Haemocytometer 
Cells were counted and assessed for viability using a haemocytometer counting chamber 
(Hawksley, Sussex, UK). An aliquot of the cell suspension was mixed with an equal volume of 
trypan blue solution (GE Healthcare, Chicago, USA) and transferred into the counting chamber. 
Dead cells were identified by their blue colour, whilst live cells remained bright. Live cells were 
counted and total cell number was calculated using the following equation: 
Total cell # = Average Cell Count × Dilution Factor × 104 
 
2.2.3 Storage and Retrieval of Cells from Liquid Nitrogen 
To freeze, cells were resuspended in cold freezing medium containing 10% (v/v) dimethyl 
sulphoxide (DMSO; Santa Cruz Biotechnology, Dallas, USA) in FCS. Freezing was performed 
at maximum 5 x106 cell per 1 ml in Cryo.S™ cryovials (Greiner Bio-One, Kremsmuenster, 
Austria) which were then placed in a Nalgene Freezing Container filled with isopropanol (Fisher 
Scientific, Loughborough, UK) overnight. The next day, cryovials were moved to liquid nitrogen 
for long-term storage. 
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To retrieve cells from liquid nitrogen, they were quickly thawed at 37˚C and diluted in 20 ml CM. 
After centrifuging at 1200 rpm for 5 minutes the pellets were resuspended gently using CM. 
Following this, the cells were transferred into T25 tissue culture flasks and kept in a humidified 
incubator at 37˚C and 5% CO2 atmosphere. 
2.2.4 Tumour Cells  
2.2.4.1 Irradiation of Renca Cells 
Renca cells were irradiated prior to peptide pulsing. Renca cells were harvested and counted. 
Cells were resuspended at 1 x106 cells/ml in CM and irradiated with 9600 Rads for 2.5 hours 
using a Cs137 source of gamma irradiation unit (RX30/55; Gravatom Projects, Grosport, UK). 
Following this, the cells were washed in RPMI 1640, centrifuged and re-suspended in CM. 
2.2.4.2 Mitomycin C Treatment of P815 cells 
P815 cells were treated with Mytomycin C prior to peptide pulsing. Mitomycin C (Sigma-Aldrich) 
was added at a final concentration of 2 μg/ml to 70 - 80% dense cultures and incubated at 37˚C 
and 5% CO2 atmosphere overnight. The following day, cells were washed in RPMI 1640, 
centrifuged and re-suspended to 1 x106 cells/ml in CM. 
2.2.4.3 Peptide Pulsing of Tumour Cells 
Renca and P815 cells were prepared for peptide pulsing as described in section 2.2.4.1 and 
2.2.4.2, respectively. The chosen peptide concentration was added into prepared cells and 
incubated for 1 hour in a humidified incubator at 37˚C and 5% CO2 atmosphere. The pulsed 
cells were then washed twice and resuspended in CM for culturing with naïve CD8+ T cells. 
2.2.5 CL4 CD8+ T Cells 
2.2.5.1 Isolation of Lymphocytes from Peripheral Lymphoid Tissue 
Hon Lam kindly assisted often in the processing of spleens and subsequent experimental in 
vitro treatments. 
Spleens were collected from CL4 mice using sterile instruments and kept in RPMI.  
Spleens were cut into small pieces with sterile scissors and, using sterile syringe plungers, were 
mashed through 40 μm cell strainers (Corning Falcon, Corning, USA) into 35 mm Cell Culture 
Dishes (Corning). This was repeated several times while washing with CM. The cell suspension 
was collected into a 50 ml conical tube and the Petri dish was rinsed with CM. Red blood cells 
were lysed using 1 ml Ack Lysing Buffer (Thermo Fisher) per spleen used. Lysis was stopped 
after 3 minutes by adding 10 ml CM and 10 ml PBS.  
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2.2.5.2 Magnetic-Activated Cell Sorting 
CD8+ cells were positively enriched using Magnetic-activated cell sorting (MACS). The 
lymphocyte mixture was magnetically labelled using anti-CD8a MicroBeads (Miltenyi) by 
resuspending cells in 45 μl MACS buffer and 5 μl microbeads per 10 x106 cells and incubating 
for 30 minutes at 4˚C. CD8a+ cells were then isolated using the Miltenyi MidiMACS Separator, 
MidiMACS LS columns (Miltenyi) and MACS buffer. Unbound beads were removed by adding 
10 ml cold MACS buffer and centrifuging for 5 minutes at 1400 rpm at 4˚C. Cells were 
resuspended in cold MACS buffer, applied to a LS separation column that was previously 
washed with 6 ml MACS buffer and placed into a MidiMACS Separator. Re-application of run-
through eluent was performed to minimize loss of CD8+ cells. The column was washed with 9 
ml MACS buffer and removed from the magnet. Magnetically-labelled cells in the column were 
flushed out by forcing 6 ml MACS buffer through with a plunger. Enrichment Purity of this method 
was routinely tested by taking a sample before magnetic labelling and one after MACS, followed 
by staining with Vβ8.1 and CD8α mAbs (see Cell Surface Staining below). Purity was routinely 
~95% (shown in Figure 6.3 in the Appendix). 
2.2.5.3 Labelling with CellTrace™ Violet 
In proliferative assays, cells were labelled with the cell tracking dye CellTrace™ Violet (CTV; 
ThermoFisher). Vials were reconstituted with 20 μl DMSO and stored at -20˚C. Purified CL4 
CD8+ T cells were pelleted and resuspended at 4 x106 cells/ml in PBS, then mixed with 1 μl/ml 
CTV and incubated in the dark at 37˚C for 20 minutes. Cells were quenched with CM and were 
let to settle for 15 minutes at room temperature and spun down. For in vitro cultures cells were 
resuspended at 1x106 cells/ml in CM, while for in vivo experiments cells were resuspended at 
3-5x106 cells/ml in PBS.  
2.2.6 Priming in vitro 
2.2.6.1 CL4 CD8+ T cell Priming with Anti-CD3 plus Anti-CD28 Monoclonal Antibodies 
CL4 naïve T cells obtained from MACS were activated using plate-bound anti-CD3 in vivo mAb 
(145-2C11; BioXCell, Lebanon, USA) and soluble anti-CD28 in vivo mAb (37.51; BioXCell). 24-
well plates (Corning) were coated by adding 250 μl of 10ug/ml anti-CD3 mAb per well and 
leaving overnight at 4˚C. The following day, unbound antibody was removed and 1x106 purified, 
in some cases CTV-labelled CL4 T cells were added to each well. Additionally, 250 μl soluble 
anti-CD28 was added to each well for a final assay concentration of 1ug/ml. Cells were cultured 
for either 48, 72 or 96 hours in CM, and maintained in a humidified incubator at 37˚C and 5% 
CO2 atmosphere.  
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2.2.6.2 CL4 CD8+ T cell Priming using Peptide-Pulsed Tumour cells 
Naïve CL4 T cells obtained from MACS and labelled with CTV (described above) were co-
cultured directly with peptide-pulsed Renca or P815 cells. T cells were mixed with tumour cells 
1:10 in flat-bottomed 24-well plates. Cells were cultured for 48 or 72 hours in CM and maintained 
in a humidified incubator at 37˚C and 5% CO2 atmosphere. 
2.2.6.3 Pulsed Splenocyte reaction (PSR) 
Spleens were collected and macerated as before. Following erythrocyte lysis, cells were stained 
with CTV (above). 4 -5 x106 cells were added into each well of a 24-well plate in CM. Cells were 
then pulsed with the chosen concentration of peptide overnight. The next day cells were 
collected, washed 5 times with RPMI 1640 to remove free peptide and resuspended in IL-2 
media at 4-5 x106 cells per well. On subsequent days fresh IL-2 media was added where 
necessary. Cells were cultured for 48, 72 or 96 hours in a humidified incubator at 37˚C and 5% 
CO2 atmosphere. 
2.2.6.4 NECA Treatment of CL4 cultures 
In some experiments, CL4 T cell cultures were treated with pan-adenosine receptor agonist 5′-
(N-Ethylcarboxamido) adenosine (NECA) (Sigma-Aldrich). NECA in DMSO was added to the 
culture at either 1 μM, 5 μM, 10 μM, 20 μM or 50 μM final assay concentration. NECA was 
added either at day 0 when CL4 T cells were naïve or after 24 or 48 hours of culture. 
2.2.7 Fluorescence-Activated Cell Sorting (FACS) 
Cells were stained for viability and cell surface markers in either round-bottom FACS tubes 
(Corning) or 96-well V-bottom plates (Thermo Fisher). 
2.2.7.1 Viability Staining 
Zombie NIR™ Fixable Viability Kit (Biolegend) was used to distinguish dead cells from live cells. 
The kit was brought to room temperature, 100 μl DMSO were added to one vial of dye for 
reconstitution and the vial was stored at -20˚C. Viability staining was carried out at a 1:100 
concentration of 1 μl prepared dye per 1x106 cells. The dye was mixed with the cells and after 
15 minutes incubation at room temperature in the dark, cells were washed twice using FACS 
buffer.  
2.2.7.2 Cell Surface Staining 
Cell surface staining was performed using fluorescently labelled mAbs. Where needed, non-
specific binding of mAbs to Fc receptors was blocked using mouse BD Fc Block™ (2.4G2; BD 
Biosciences) by mixing with the cells, incubating for 15 minutes at 4˚C and washing with FACS 
buffer. Cells were then spun down for 5 minutes at 1400 rpm and resuspended in fluorochrome-
Chapter 2 - Materials and Methods 
26 
 
conjugated mAbs using the optimum concentrations as listed in Table 6.1. After 30 minutes 
incubation in the dark at 4˚C, cells were washed twice using FACS buffer and fixed in 1% PFA.  
2.2.7.3 Fluorescence-Activated Cell Sorting (FACS) 
Stained samples were fixed with 1% paraformaldehyde (PFA) until analysis. Fluorochrome-
labelled cells were acquired using LSRII, Fortessa X 20 with Diva software (BD Biosciences) or 
Novocyte with NovoExpress software (ACEA Biosciences). Data was analysed using FlowJo™ 
software v10.3 and FMOs were used for gating (FlowJo, Ashland, USA). 
2.2.8 Statistical Analysis 
Statistical analysis was carried out using IBM SPSS Statistics v25 (IBM, New York, USA). 
Values of p≤0.05 were deemed significant, while p>0.05 was considered not significant. To 
compare two groups, unpaired t-test was used, while for three or more groups one-way or two-
way ANOVA was used as indicated. For multiple comparisons between groups, further analyses 
were conducted. Microsoft Excel was used in the analysis of some experiments. All graphs were 
created using GraphPad Prism software v7.04 (GraphPad, California, USA). Error bars on 
graphs indicate ±SEM. 
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Chapter 3 - The Effect of NECA on CD8+ T Cells 
3.1 Background 
Once CD8+ T cells have been primed against tumour-specific antigens and activated, they 
migrate to the site of the tumour to infiltrate it and attempt to eliminate the malignant cells. 
However once there, they enter a tumour-tolerant state and whilst activated, do not kill any 
cancer cells. This is due to the TME and its extreme immunosuppressive conditions. High levels 
of extracellular adenosine, amongst other immunosuppressive factors, largely contribute to the 
non-functional and exhausted phenotype of CD8+ T cells which display an inability to proliferate 
or produce effector cytokines IL-2 and IFN-γ.  
Adenosine is of immunosuppressive nature; by recruitment of immunoregulatory cells (e.g. Treg 
cells) and upregulation of anti-inflammatory factors, at moderate concentrations it plays an 
important role in the modulation of immune responses (36, 43, 122). Many immune cells express 
the adenosine receptor A2AR, which when activated by adenosine acts as a negative regulator 
of their functions (49). High rates of ATP and AMP hydrolysis in the TME lead to accumulation 
of high adenosine concentrations which interfere with the anti-tumour ability of CTLs. 
Whilst under normal conditions CIRs are expressed to prevent potentially harmful overactivity 
of T cells, T cell exhaustion is associated with increased expression of receptors like PD1, TIM3, 
TIGIT and LAG3 on the CD8+ T cell surface (67). Upregulation of these receptors has been 
shown to correlate with poor prognoses of several cancers, such as renal cell carcinomas (123). 
Different combinations of CIR expression also play an important role in the success of cancer 
treatments (94, 124). Co-expression of TIM3 and PD1 has been observed on TILs in the TME 
from patients with cancers like metastatic melanoma, non-small cell lung and renal cell 
carcinoma (68). This combination is most commonly found on exhausted TILs. PD1+LAG3+ 
CD8+ T have also been shown to be more dysfunctional than exhausted PD1+ or LAG3+ only 
CD8+ T cells (125). Aside from this, CIR co-expression plays an important role in the 
immunosuppressive nature of the TME. TIM3+PD1+ Treg cells have been found to be highly 
immunosuppressive, highlighting the suppressive power of this receptor combination. 
Due to the rapid metabolism of adenosine by adenosine deaminase in an experimental setting 
(126), in these investigations 5′-(N-Ethylcarboxamido) adenosine (NECA) was used. NECA is a 
synthetic adenosine analogue which cannot be hydrolysed and acts as an A1 and A2 receptor 
agonist, with equal affinity for both receptors. 




I. To assess the effect of NECA at different concentrations on the expression of 
TIM3, TIGIT, LAG3 and PD1 on CD8+ cells  
II. To examine the effect of NECA on the proliferation of CD8+ T cells and if this varies 
depending on the addition time of NECA to the culture  
III. To investigate the changes in expression of TIM3, TIGIT, LAG3 and PD1 on CD8+ 
T cells as they activate in vitro using either anti-CD3 and anti-CD28 mAbs or a 
pulsed splenocyte reaction 
3.3 How does NECA influence CD8+ T cell proliferation? 
Exhaustion of anti-tumour CD8+ T cells is characterised by their inability to perform effector 
functions, such as secretion of effector cytokines IL-2 and IFN-γ, as well as loss of their ability 
to proliferate. High extracellular levels of adenosine inhibit effector function of CTLs by 
interfering with their recognition of and adhesion to target cells (37, 43). Additionally, 
engagement of the A2AR on CTLs has been shown to inhibit their ability to perform cytolytic 
functions (25). Thus, since adenosine is a key contributor to the immunosuppressive nature of 
the TME, it was interesting to assess how different concentrations of NECA would influence the 
ability of CD8+ T cells to proliferate.  
3.3.1 Investigating the effect of NECA on the proliferation of CD8+ T cells 
To determine whether or not NECA affects the proliferation of CD8+ T cells, naïve CD8+ T cells 
were purified using MACS and CTV labelled. Cells were then primed with anti-CD3 and anti-
CD28 mAbs and cultured in the presence of 1 µM, 2 µM, 5 µM, 10 µM, 20 µM or 50 µM NECA 
for 72 hours. Harvest and staining using specific fluorochrome-labelled mAbs was performed in 
24-hour intervals (Figure 3.1). Proliferation past the first division was then analysed as shown 
in Figure 6.4. 
As shown in Figure 3.1, no statistically significant difference in proliferation was found between 
different NECA concentrations at different time points using two-way ANOVA (p≥0.05). There 
was no proliferation between 0 and 24 hours (A) as cells were still naïve. At 48 hours (C) as 
cells activated and proliferation increased rapidly, analyses showed that there was no significant 
difference between NECA-treated and untreated wells. Between 48-hour and 72-hour time 
points an increase to ~85 % was observed in NECA-treated cells, so that at 72 hours (D) cells 
treated with either 1 µM, 5 µM, 10 µM, 20 µM or 50 µM of NECA had proliferated without any 
statistically significant differences to untreated control cells. Thus, the statistical analysis of the 
data indicated that NECA does not affect CD8+ T cell proliferation at any of the 5 concentrations. 
However, it is important to note that despite the lack of statistical confidence, graph (C) suggests 
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that the proliferation of CD8+ cells was impaired most (10 % proliferated cells) at 48 hours when 
treated with 50 µM NECA. ~30 % of CD8+ T cells had proliferated when cultured in the presence 
of 1 µM, 5 µM, 10 µM or 20 µM NECA, compared to nearly 60 % in untreated cells. As shown 
in (D), by 72 hours untreated and NECA-treated CD8+ T cells had highly proliferated; ~ 90% of 
untreated CD8+ T cells had proliferated, and 85-90 % of cells treated with 1 µM, 5 µM, 10 µM 
or 20 µM NECA had proliferated. Also ~75 % of CD8+ T cells cultured in the presence of 50 µM 
NECA had proliferated. This suggests that the presence of NECA during activation of CD8+ T 
cells elicits a lag in their proliferation, however by 72 hours cells had recovered and displayed 
similar levels of proliferation as untreated cells. CTLs undergo activation in the peripheral 
lymphoid organs, such as the spleen, and subsequently travel to the tumour site. Therefore, 
they encounter high adenosine concentrations in the TME after they are activated. This is an 
important point to consider with these results, since CD8+ T cells in this experiment were 
cultured in the presence of NECA from a naïve state onwards. Thus, it was important to assess 
how NECA affects the proliferation of activated CD8+ T cells.  




Figure 3.1- The effect of NECA on the proliferation of CD8+ T Cells 
(A) MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were primed using anti-CD3 and anti-
CD28 mAbs. NECA was added at different concentrations (1 µM, 2 µM, 5 µM, 10 µM, 20 µM or 
50 µM) at 0 hours and cultures were incubated for 72 hours, whilst cells were harvested every 
24 hours. 
(B), (C) and (D) show 24-hour, 48-hour, 72-hour time points in more detail, respectively. 
Error bars represent mean ±SEM. Data is representative of 2 separate experiments using 3 
technical repeats in each experiment. Data was statistically analysed using two-way ANOVA 
followed by Bonferroni multiple comparison test.  
ns = not significant (p≥0.05) 















































































































































Figure 3.1 - The effect of NECA on the proliferation of CD8+ T Tells 
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3.3.2 At what time point during priming does NECA affect proliferation? 
After encountering APCs presenting tumour antigen and undergoing activation in tumour-
draining lymph nodes, CTLs enter the TME. After being subjected to the inhibitory environment 
CTLs become exhausted and thus tumour-tolerant, losing their ability to perform effector 
functions. Since cells typically enter the TME and thus encounter high adenosine levels once 
they are activated, NECA was added to cell culture at different points during activation to mimic 
this. Hence, to determine whether addition time of NECA influenced its effect on CD8+ cell 
proliferation, naïve CD8+ T cells were purified using MACS, labelled with CTV and primed using 
anti-CD3 and anti-CD28 mAbs. NECA was then added to the culture at either 0 hours, 24 hours 
or 48 hours of culture and cells were harvested at 72 hours (Figure 3.2).  
  
Figure 3.2 – At what time point during priming does NECA affect proliferation? 
MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were cultured in the presence of anti-
CD3 and anti-CD28 mAbs. NECA was added at different concentrations as shown. Cells were 
harvested at 72 hours. 
Error bars represent mean ±SEM. Data is representative of 3 separate experiments using 3 
technical repeats in each experiment. Statistical analyses were carried out using one-way 
ANOVA followed by Bonferroni multiple comparison test. 






























































































(A) Addition of NECA at 0 hr (B) Addition of NECA at 24 hr
(C) Addition of NECA at 48 hr
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One-way ANOVA determined the differences between NECA concentrations not statistically 
significant when added at 0 hours (p≥0.05). This concurs with our initial findings; when NECA 
is when cells are still naïve (A), at 72 hours there is no difference between NECA-treated and 
untreated cells. However, this was also observed when NECA was added at 24 hours (B), as 
cells were just beginning to undergo activation. CD8+ T cells cultured in the presence of 1 µM 
or 20 µM NECA from 24 hours onwards had proliferated to the same extent as untreated cells 
by 72 hours (p≥0.05). Also when NECA was added at 48 hours (C), when cells were sufficiently 
activated, by 72 hours there was no significant difference between the proliferation of NECA-
treated and of untreated CD8+ T cells (p≥0.05). Thus, unexpectedly the time of NECA addition 
appeared to have no effect on CD8+ cell proliferation. 
3.4 Does NECA affect the expression of coinhibitory receptors on CD8+ 
T cells? 
Due to the immunosuppressive nature of adenosine, it was necessary to assess how it affected 
naïve and activated CD8+ T cells and influenced them towards an exhausted phenotype. It is 
crucial to understand the interplay of immunosuppressive factors present in the TME to be able 
to develop effective therapies targeting them. Based on the interference of adenosine with CTL 
effector functions, we examined whether there is a relationship between high levels of 
adenosine and the expression of CIRs on the CTL surface. 
3.4.1 The effect of priming on coinhibitory receptor expression on naïve CD8+ T cells 
Coinhibitory receptors are upregulated on the CD8+ T cell surface not only when they are 
exhausted, but their expression also changes during activation. Hence, in addition to 
investigating how NECA affects coinhibitory receptor expression on CD8+ T cells, how the 
expression of these markers changed as CD8+ T cells activate was assessed. Thus, to assess 
the expression of TIM3, TIGIT, LAG3 and PD1 on CD8+ T cells during activation and whether 
this varied depending on their environment during activation, cells were primed using two 
different methods. Naïve CL4 CD8+ T cells were labelled with CTV and primed using either 
KdHA peptide-pulsed splenocyte reaction (PSR) or by using plate-bound anti-CD3 and soluble 
anti-CD28 mAbs. Cells were then stained at 24-hour intervals over 96 hours with specific 
fluorochrome-labelled mAbs (Figure 3.3). 
One-way ANOVA found no significant differences between the changes of TIM3 expression (A) 
when cells were activated using monoclonal anti-CD3 and anti-CD28 mAbs (p≥0.05). However, 
in PSR, differences in TIM3 expression were found to be significant (p≤0.001). Between 24- and 
48-hour time points TIM3 rose from 10% to approximately 30%, i.e. when cells are undergoing 
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rapid activation. Subsequently expression plateaued, with no significant differences in TIM3 
expression between 48, 72 and 96 hours. 
There was a statistically significant difference between TIGIT expression changes (B) when 
cells were activated by anti-CD3 and anti-CD28 mAbs (p≤0.01), also when activated using PSR 
(p≤0.01). When cells were primed using anti-CD3 and anti-CD28 mAbs, there was a significant 
increase in TIGIT expression between 48-hour and 72-hour time points. Then, after 72 hours 
TIGIT expression had reached a maximum of approximately 40% which stayed the same at 96 
hours with no significant difference. During PSR priming no significant changes between 
subsequent time points were observed, apart from an overall increase by 30% between 0 hours 
and 48 hours, until TIGIT expression dropped off steeply from 35% to 10% between 72 and 96 
hours of culture. 
Analyses of differences in LAG3 expression (C) found statistically significant differences when 
cells were activated using anti-CD3 and anti-CD28 mAbs (p≤0.01) as well as when cells were 
primed using PSR (p≤0.001). Following activation using anti-CD3 and anti-CD28 mAbs, LAG3 
expression increased after 24 hours and plateaued at approximately 40% over the subsequent 
time points.  When CD8+ T cells were primed using PSR, LAG3 levels rose to 55% percentage 
between 0-hour and 24-hour time points and peaked at 48 hours at ~85%. Following this, at 72 
hours expression had decreased to 30% percentage but a rise of 10% was seen again at 96 
hours. 
Differences in PD1 expression (D) were found to be statistically significant when CD8+ T cells 
were activated using anti-CD3 and anti-CD28 mAbs (p≤0.001). PD1 expression increased 
steadily until it peaked at 38% at 72 hours. Following this, there was a 20% decrease between 
the 72-hour and 96-hour time point. Changes in PD1 expression changes were also significant 
when cells were primed using PSR (p<0.05). PD1 was upregulated to 35% at 24 hours when 
cells were beginning to activate, however subsequently expression decreased to ~10% and 
stayed at this level for the 72- and 96-hour time points. 
Whilst increases of CIRs are seen when cells are primed by either method, it appears that in 
the setting of a PSR coinhibitory receptors, especially TIM3, TIGIT and PD1, are downregulated 
after activation (by 72 and 96 hours). This stands in contrast with the levelling of CIR expression 
observed in anti-CD3 and anti-CD28 priming, despite this plateau occurring at different 
expression levels of the CIRs. This could be due to the mixture of splenocytes present in this 
KdHA peptide-pulsed (PSR) culture method, such as dendritic cells or macrophages, influencing 
CD8+ cells to downregulate the suppressive surface markers.   
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  Figure 3.3 - The changes in expression of coinhibitory receptors on CD8+ T cells during 
activation 
Naïve CL4 CD8+ T cells were primed in vitro using either a KdHA peptide-pulsed splenocyte 
reaction (PSR) or by culturing with anti-CD3 and anti-CD28 mAbs. For PSR, cells were labelled 
with CTV and then plated, whilst cells activated with antibodies were MACS-purified first. 
Cultures were incubated up to 96 hours, with cells being harvested every 24 hours and prepared 
for flow cytometry analysis using fluorochrome-labelled mAbs specific for (A) TIM3, (B) TIGIT, 
(C) LAG3 or (D) PD1. 
Error bars represent mean ±SEM. Data is representative of 3 separate experiments using 3 
technical repeats in each experiment. Statistical analysis was carried out using one-way 

















































































































































































































Cells primed using 
Anti-CD3 and Anti-CD28 mAbs PSR 
Figure 3.3 - The changes in expression of coinhibitory receptors on CD8+ T cells during 
activation 
Chapter 3 - The Effect of NECA on CD8+ T Cells 
37 
 
3.4.2 Does NECA affect the expression of coinhibitory receptors on CD8+ T cells? 
After establishing the expression patterns of CIRs during priming, we assessed whether this 
would be impacted by NECA. CTL exhaustion has been associated with elevated levels of 
coinhibitory receptors on the CD8+ T cell surface. Since it is likely that the exhausted phenotype 
is contributed to by elevated levels of adenosine in the TME, it was important to investigate how 
NECA affected the expression of CIRs of CD8+ T cells directly.  
To determine the effect of NECA on the expression of TIM3, TIGIT, LAG3 or PD1 on CD8+ T 
cells as they activate, naïve CL4 CD8+ T cells were purified using MACS and labelled with CTV. 
These were then primed using anti-CD3 and anti-CD28 mAbs, at which point NECA was added 
at 1 µM, 2 µM, 5 µM, 10 µM, 20 µM or 50 µM). Cells were cultured for 72 hours, with harvest 
and staining using specific mAbs occurring every 24 hours (Figure 3.4). 
Analysis of the data revealed no statistically significant difference between different 
concentrations of NECA at different time points on the expression of TIM3 (p≥0.05) or the 
expression of TIGIT (p≥0.05) as determined by two-way ANOVA. The varying NECA 
concentrations had no effect on TIM3 or TIGIT expression and both receptors were expressed 
at a low level (between 10-20% expression) throughout culture time in NECA-treated and 
untreated wells. Further, two-way ANOVA found a statistically significant effect of different 
NECA concentrations at different time points on the expression of LAG3 (p≤0.001) and on the 
expression of PD1 (p≤0.001). LAG3 levels decreased as NECA concentration increased at 24 
hours (B). 50 µM had the biggest effect on LAG3 expression, with higher NECA concentrations 
dampening LAG3 expression most at 24 hours and 48 hours. NECA concentrations 1 µM, 10 
µM, 20 µM and 50 µM significantly decreased LAG3 expression at 48 hours (C). However, by 
72 hours, this effect was reversed as LAG3 levels on NECA-treated and on untreated cells 
showed no significant difference.  
A similar pattern could be observed for PD1 expression. Higher NECA concentrations (10 µM, 
20 µM and 50 µM) significantly lowered PD1 expression from 55% in untreated cells to 
expression less than 30% after 24 and from 80% in untreated cells to less than 65% after 48 
hours of culture, as shown in (B) and (C), respectively. At 72 hours, again there was no 
significant difference between untreated and treated cells (D). 1 µM and 5 µM concentrations 
had no effect on the expression pattern of PD1 at any time point. 
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Figure 3.4 - The effect of NECA on the expression of coinhibitory receptors on CD8+ T 
cells 
(A) MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were primed using anti-CD3 and anti-
CD28 mAbs. NECA was added at different concentrations (1 µM, 2 µM, 5 µM, 10 µM, 20 µM or 
50 µM) at 0 hours and cultures were incubated for 72 hours. Cells were harvested and stained 
using fluorochrome-labelled mAbs specific for TIM3, TIGIT, LAG3 or PD1 every 24 hours. 
(B), (C) and (D) show 24-hour, 48-hour, 72-hour time points in more detail, respectively. 
Error bars represent mean ±SEM. Data is representative of 2 separate experiments using 3 
technical repeats in each experiment. Data was statistically analysed using two-way ANOVA 




ns = not significant (p≥0.05) 
 







































































































































































Figure 3.4 - The effect of NECA on the expression of coinhibitory receptors on CD8+ T cells 





























































































































































































Figure 3.4 - The effect of NECA on the expression of coinhibitory receptors on CD8+ T cells 




The combination of several immunosuppressive and inhibitory factors present in the TME, such 
as high levels of extracellular adenosine in the tumour surroundings, drive anti-tumour CD8+ 
cells towards a tumour-tolerant and exhausted phenotype, slowing continued tumour growth. 
This exhausted state is hallmarked by a loss of effector functions, such as proliferation and 
production of effector cytokines IL-2 and IFN-, and the upregulation of coinhibitory receptors 
on the surface of CD8+ T cells residing in the tumour. Under normal conditions, these receptors 
help regulate T cell activity to prevent overactivity, however in a tumour setting this brake is 
taken advantage of by preventing the killing of malignant cells. 
Here we assessed the effects of NECA on different aspects of CD8+ T cells, such as their 
proliferative ability and the expression of CIRs on their cell surface. Although CIRs are often 
described as being upregulated during CD8+ T cell activation, the exact trends of their 
expression are not described in detail. The prediction of biomarkers is essential in 
immunotherapy; furthering the understanding of CIR expression patterns would allow for 
targeting of therapies to them. 
We showed the patterns of TIM3, TIGIT, LAG3 and PD1 expression during CD8+ T cell 
activation and found that in a mixture of splenic cells in culture CIR expression was 
downregulated after activation. This pattern was not observed when CD8+ T cells alone were 
activated via stimulation of CD3 and CD28 only, confirming that the surrounding immune cells 
influence CD8+ T cells and encourage their functionality. Additionally, our findings suggested 
that NECA has no effect on either the expression of these markers of exhaustion or on CD8+ T 
cell proliferation, even at concentrations higher than those encountered in the TME. These were 
unexpected findings, since adenosine is known to have an immunosuppressive effect on T cells 
(43, 48). 
In the TME, adenosine very likely acts in concert with other immunosuppressive factors and its 
effects on coinhibitory receptors may therefore be mediated in a secondary manner rather than 
affecting CTLs directly. Further, it is also possible that these two inhibitory mechanisms do not 
interplay but act separately on CTLs instead. This premise is supported by studies in which 
tumour metastases were inhibited using a combination of adenosine receptor as well as CIR 
blockade (127). High concentrations of adenosine (typically higher than 50 µM) have been 
shown to act via the A2A receptor to suppress some T cell functions (128, 129), whilst some 
studies have found that the A3 adenosine receptor may also be involved in the suppression of 
CD8+ T cell activity at lower adenosine concentrations (43). In this case, these effects would 
not be mimicked using NECA since it is an A1 and A2 agonist. Thus, it should be investigated 
whether stimulation of A3 affects proliferation or CIR expression on CD8+ T cells. Further, 
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expression of CIRs increases in the presence of their ligands, which are upregulated on tumour 
and other immune cells. Thus, it is likely that the lack of ligands for TIM3, TIGIT, LAG3 and PD1 
in our experimental setting discouraged their upregulation despite stimulation of adenosinergic 
receptors on the CD8+ T cell surface.   
In conclusion, we found that stimulation of A1 and A2 receptors using NECA had no effect on 
CD8+ T cell proliferation or expression of TIM3, TIGIT, LAG3 or PD1 even at high 
concentrations. With these findings in mind, it is important to establish how adenosine affects 
anti-tumour CD8+ T cells. Further, although its role is debated, the effect of A3 receptor 
engagement should be investigated. It is important to understand expression patterns of CIRs 
as well as mechanisms of suppression via adenosine to be able to successfully target these in 
cancer therapies.  
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Chapter 4 - Priming CD8+ T Cells using SAGEs 
4.1 Background 
Cancer immunotherapies are aimed at utilising and enhancing the host’s own immune system. 
This makes immunotherapy less invasive and allows potential targeting of therapies, thus 
reducing side effects experienced by the patient than when compared to traditional therapies. 
Vaccines to help mount sufficient anti-tumour immune responses are actively being 
investigated, with the goal of potentiating or restoring tumour immunity. Several studies have 
found that the presence of high numbers of TILs in tumours indicates good prognoses in several 
cancers (81-85). This highlights the need of tumour vaccines to stimulate tumour-antigen-
specific proliferation of CTLs to provide large numbers of these cells exhibiting effective 
cytotoxic functions and to establish memory T cells to provide long-term immunity. In order to 
achieve this, different parts of the anti-tumour immune response can be targeted. This may 
include DCs since these cells are considered professional APCs due to their efficiency in antigen 
uptake and presentation via MHC class molecules (130, 131). Immature DCs are able to capture 
antigen, however upon presentation of antigen to T cells no costimulatory signals are provided 
(130). Immature DCs are associated with the induction of tolerance and immunosuppressive 
characteristics (130, 132). On the other hand, mature (activated) DCs present antigen-MHC 
molecule complexes to the TCR and provide costimulation via B7.1 and B7.2 to activate naïve 
CD8+ T cells and initiate their differentiation to CTLs (132). Thus, cancer vaccines are often 
targeted to this step, in order to initiate proliferation of CTLs primed against tumours and gain 
large CTL numbers. This may be achieved by injection of DCs that have prior been pulsed with 
tumour-antigen in order to promote T cell immunity (133, 134). 
Early attempts at tumour vaccinations used short peptides, often without using an effective 
adjuvant, to activate DCs which did not prove promising. This was likely due to particles being 
cleared before DCs had the opportunity to internalise them and the lack of activation triggered 
a steady state in DCs. Adding immune stimulants into the equation has been shown to increase 
the effectiveness of cancer vaccines (15). However, as knowledge of tumour immunology 
advances, more hurdles are identified in the development of effective cancer vaccines. Firstly, 
the tumour antigen to be used must be considered. Ideally, this antigen is expressed highly on 
tumours in many patients with the same cancer whilst found not at all or only low levels on 
healthy tissue. In addition, the ideal tumour antigen is vital for the tumour’s growth or survival 
(to reduce chances of immune evasion) (15, 109). Another difficulty in developing a potent and 
effective cancer vaccine lies in that the vaccine needs to break the tumour-induced tolerance of 
anti-tumour immune cells successfully. In order to do so, the vaccine must deliver large 
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quantities of antigen to DCs, stimulate their expansion and provide DC activation signals (109). 
Subsequently, activated DCs should migrate to the lymph nodes to present the antigen to Cd8+ 
T cells to then activate these strongly to ensure high TCR affinity and effective cytotoxic 
functions (15, 109).  
Vaccination of free peptide with adjuvant can counterproductively lead to tolerance of CD8+ T 
cells. This is likely due to the distribution of peptide systemically causing overstimulation and 
subsequent cell death of specific CD8+ cells. Thus, if the peptide is delivered to the target in a 
contained manner, this improves the cytotoxic cell response (135). 
SAGE particles are synthetic nanoparticles consisting of short, de novo α-helical peptides. Self-
assembly out of two complementary hubs (a heterodimer and a homotrimer) creates closed 
networks that allow the attachment or enclosure of material (117). Due to the interchangeability 
of their components, SAGEs and their potential applications can be highly versatile, such as the 
delivery of drugs or biomolecules (115, 117). By attaching tumour antigens to SAGEs, these 
could be used as tumour vaccines. Recent studies using SAGEs have shown their immunogenic 
potential; SAGEs can be targeted to and be taken up by APCs in vitro. Further, SAGEs elicited 
antigen-specific proliferative responses from CD4+ and B cells in vivo (116). 
In this study, we tested the ability of peptide-conjugated SAGEs to activate effector functions of 
CD8+ T cells in vivo. Functionalisation of the particles with peptides specific to the CL4 TCR 
allowed the targeting to specific CD8+ T cells. For this, three different-length peptides were 
used. Epitope (EP) peptide (H-IYSTVASSL-OH) was synthesised based on KdHA peptide 
(518IYSTVASSL526) serving as a specific peptide to be recognised by the TCR expressed on CL4 
CD8+ T cells. Further, POL (H-AVGAGATAEEIYSTVASSL-OH) and Leader (LEA) peptides 
(H-EKLAGFGAVGAGATAEEIYSTVASSL-OH) were used. De Haan et al (2002) used a loop 
segment derived from the DNA polymerase of the herpes simplex virus type 1 to add to a subunit 
of the Escherichia coli heat-labile toxin in order to use this subunit as an epitope-delivery vehicle 
for MHC class I presentation (136). Based on this work, the mentioned loop segment containing 
hydrophobic, charged amino acids was added to the epitope sequence (EP) to give the POL 
peptide. This was done in order to be able to target the SAGE-delivered peptide for 
internalisation by APCs and into the cross-presentation pathway in vivo. Further, in addition to 
the loop segment, a cathepsin cleavage site was added. This formed the LEA peptide which 
was created to potentially improve uptake of the peptide by APCs in case the POL peptide would 
not elicit sufficient uptake by APCs.  
4.2 Aims 
I. To evaluate the ability of EP, POL and LEA peptides to activate CD8+ T cells 
Chapter 4 - Priming CD8+ T Cells using SAGEs 
45 
 
II. To evaluate the ability of POL-SAGEs to prime CD8+ T cells in vivo 
III. To establish whether POL-SAGEs can improve CD8+ T cell proliferation compared 
to POL peptide alone 
4.3 Testing EP, POL and LEA peptides for their ability to prime CD8+ T 
cells 
In order to determine the ability of EP, POL and LEA peptide to activate CD8+ T cells, Renca 
cells were pulsed with each of the peptides. Following this, Renca cells were co-cultured with 
CD8+ T cells that had previously been purified using MACS and labelled with CTV. Cultures 
were incubated for 72 hours, whilst cells were harvested and stained for flow cytometry using 
specific mAbs every 24 hours (Figure 4.1). One-way ANOVA found a significant difference in 
levels of activation over time for each peptide (p≤0.001). In general, proliferation of CD8+ T cells 
in EP-pulsed wells was significantly lower than the proliferation observed in wells with the longer 
peptides POL or LEA. EP and POL peptides did not activate CD8+ T cells as well as the positive 
control, but the proliferation of cells observed in wells with LEA showed no difference to that of 
the positive control. CTV histograms between wells with positive control and with LEA-pulsed 
Renca cells are near identical, as shown in (C). Furthermore, CD8+ T cells cultured with POL- 
and LEA-pulsed Renca cells were highly divided, with LEA exhibiting the most divided cells. 
These results were surprising since CD8+ T cells cocultured with peptide-pulsed Renca cells 
had proliferated regardless of which peptide had been added. A likely explanation is that the 
irradiation of Renca cells was incomplete or did not affect the processing ability, so that Renca 
cells were capable of taking up the peptides, processing and displaying them to CD8+ cells. 
This concurs with LEA causing the highest proliferation of all three peptides since it is the longest 
one and thus would be more likely to be processed. 
To be able to assess whether EP, POL and LEA are able to prime CD8+ T cells without potential 
processing of the peptides, the experiment was altered to use P815 mastocytoma cells instead 
of irradiated Renca cells. These cells possess MHC class I molecules to present the peptides 
to CD8+ cells (137). Thus, MACS-purified CD8+ T cells were labelled with CTV and co-cultured 
with EP-, POL- or LEA-pulsed P815 cells. Cells were harvested and stained using specific 
fluorochrome-labelled mAbs for flow cytometry every 24 hours over a total culture time of 72 
hours (Figure 4.2). As the time course (A) shows, the percentages of cells divided were similar 
between EP, POL and LEA at each time point. Initially there were no divided cells at 24 hours 
which changed by 48 hours as a steep rise could be seen when cells activated. At 72 hours 
there were no significant differences in percentage of cells proliferated past the first division 
between the peptides. As shown in the histogram (B), successive CTV peaks of cells cultured 
in the presence of LEA- or POL-pulsed P815 cells are higher than those with EP-pulsed P815 
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cells. This suggests that LEA- or POL-pulsed P815 cells elicited more highly divided CD8+ T 
cells than EP-pulsed P815 cells, concurring with observations described in Figure 4.1. It seems 
unlikely that the longer peptides, especially LEA, were able to be directly presented by MHC 
class I molecule and thus be recognised by TCR since the optimal peptide length for the TCR 
to recognise is between 8 - 10 amino acid residues (138, 139). Whilst longer peptides may still 
be recognised, it would not be anticipated that subsequent CD8+ T cell activation would be of 
the same magnitude as one from a much shorter peptide (140). Thus, these observations 
suggest degradation of the longer peptides (into EP) or the presence of excess peptide in 
solution. 
  (A) 





































Figure 4.1 - Testing EP, POL and LEA peptides using Renca cells 
(A) MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were co-cultured with irradiated Renca 
cells which were peptide-pulsed with either EP, POL or LEA peptide at 1 mM or KdHA (positive 
control) or unpulsed (negative control). Cultures were incubated for 72 hours; cells were harvested 
and stained using fluorochrome-labelled mAbs specific for CD8α every 24 hours. 
(B) Histogram shows CTV profiles at 72 hours for each peptide. Gates are representative of 
percentage of cells divided past the first peak. Proliferation was measured by assessing cells past 
the first undivided peak shown in the first row. 
Error bars represent mean ±SEM. Data is representative of 3 separate experiments with 3 technical 
repeats each experiment. Statistical analyses were carried out using one-way ANOVA followed by 
unpaired t-test. 
*** p≤0.001 
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Figure 4.2 – Testing EP, POL and LEA peptides using P815 cells 
(A) MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were co-cultured with P815 cells 
which were previously mitomycin-treated and peptide-pulsed with either EP, POL or LEA 
peptide at 1 mM. The positive and negative control were co-cultured with KdHA-pulsed or 
unpulsed P815s, respectively. Cultures were incubated for 72 hours; cells were harvested and 
stained using fluorochrome-labelled mAbs specific for CD8α every 24 hours. 
(B) shows 48-hour and 72-hour time points in more detail. 
(C) Histogram shows CTV profiles at 72 hours for each peptide. Gates are representative of 
percentage of cells divided past the first peak. Proliferation was measured by assessing the 
percentage of cells divided past the first peak, as shown in Figure 6.4 in the appendix. 
Error bars represent mean ±SEM. Data is representative of 4 separate experiments with 3 
technical repeats each experiment. Statistical analyses were carried out using one-way ANOVA 
followed by unpaired t-test. 
ns = not significant (p≥0.05) 
 
 

























































































Figure 4.2 - Testing EP, POL and LEA Peptides using P815 Cells 
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4.4 Determining the optimal incubation time for CD8+ T cells in vivo 
It was important to identify the optimal length of time to incubate adoptively transferred CL4 
CD8+ T cells to use in our investigations. Thus, in order to optimise the time period for which 
CD8+ T cells would be incubated (where the majority of cells had undergone several rounds of 
cell division without losing the proliferative dye completely) in in vivo experiments, naïve CD8+ 
cells were purified using MACS, labelled with CTV and adoptively transferred into BALB/c mice. 
Following adoptive transfer, mice were inoculated with 1200 HA units of A/PR/8/H1N1 influenza 
virus. Mice were culled after either 3 or 7 days and CD8+ T cells were extracted from spleens 
(Figure 4.3). 
The data shown in Figure 4.3 shows that a higher percentage of cells had divided at day 7 than 
at day 3. As can be seen in (B), most cells had lost the CTV dye by day 7 which created two 
distinct populations, one of high CTV fluorescence and one of no CTV fluorescence. Whereas 
at day 3 clear populations of cells undergoing different rounds of divisions could be observed, 
thus this incubation time was used in subsequent experiments. 
  

































Figure 4.3 - Determining the optimal incubation time for CD8+ T cells in vivo 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified, CTV-labelled naïve CL4 CD8+ 
T cells by adoptive transfer and subsequently received approximately 1200 HA units of influenza 
virus strain A/PR/8/H1N1. After either (A) 3 or (B) 7 days CL4 CD8+ T cells were extracted from 
spleens using MACS and stained for flow cytometry.  
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4.5 Evaluating the ability of POL-SAGE to activate CD8+ T cells in vivo 
Due to the similarity in size and shape of SAGE molecules to viral particles, some 
immunogenicity may be expected of them (116). It was important to determine whether an 
immune response was elicited in this experimental setting, to be able to identify false positive 
results. 
In order to assess whether unconjugated SAGE particles would elicit a proliferative response, 
MACS-purified and CTV-labelled CD8+ T cells were cultured in the presence of SAGE particles 
for 72 hours. Cells were then harvested and stained for flow cytometry using CD8α-specific 
mAbs (Figure 4.4). 
We found no proliferation of CD8+ T cells cultured in the presence of SAGE particles. As can 
be seen in Figure 4.4, the peak seen for cells cultured with SAGE aligns with the undivided peak 
of cells in the positive control. Thus can be concluded that the parent SAGE particle alone 
cannot prime CD8+ T cells without the functionalisation with appropriate peptides. 
After establishing that the EP, POL and LEA peptides were able to prime CD8+ T cells in vitro 
(Section 4.3), we wanted to test whether peptide delivery was possible using SAGEs. Thus, it 







Figure 4.4 - Does unconjugated SAGE alone initiate CD8+ T Cell proliferation? 
MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were mixed with either unconjugated SAGE 
particles or KdHA (positive control). Cultures were incubated for 72 hours; cells were harvested and 
stained using fluorochrome-labelled mAbs specific for CD8α after this. 
Data is representative of 2 separate experiments. 
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conjugated POL-SAGEs would be able to prime CD8+ T cells sufficiently in vivo and how the 
immune response compared to a positive control. In order to do so, MACS-purified, CTV-
labelled CD8+ cells were adoptively transferred into BALB/c mice followed by inoculation with 
either influenza virus or POL-SAGE. CD8+ T cells were extracted 3 days later, stained for flow 
cytometry using specific mAbs and analysed (Figure 4.5). As seen in (C), a higher percentage 
of cells had proliferated in mice with POL-SAGE treatment than in the positive control. These 
findings suggest that POL-SAGE was able to prime CD8+ T cells in vivo and drive a strong 
proliferative response. In order to establish whether proliferation of CD8+ cells was due to POL-
SAGE particles or whether this was due to one of the SAGE constituents, adoptive transfer was 
performed in an identical manner as above in a separate experiment. This was followed by 
inoculation with either POL peptide only, unconjugated SAGE + POL peptide, or POL-SAGE 
(Figure 4.6). There were no divided CD8+ T cells in the negative control, whilst CD8+ T cells in 
the positive control had proliferated, which indicates a functioning system and that CD8+ T cells 
did not proliferate without external intervention. Results showed that the percentages of divided 
cells were very similar between the different conditions. Constructing SAGE with the POL 
peptide did not improve the proliferative response compared to peptide alone.   














































Figure 4.5 - Assessing the activation ability of POL-SAGEs in vivo 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified naïve CL4 CD8+ T cells that 
had been labelled with CTV by adoptive transfer followed by either appr. 1200 HA units of 
influenza virus strain A/PR/8/H1N1 or 1 mM of POL-SAGE. 3 days later CL4 CD8+ T cells were 
extracted from spleens using MACS and stained for flow cytometry. (A) and (B) show dot plots 
and histograms of mice injected with influenza or POL-SAGE, respectively. (C) shows a bar 
graph comparing the percentages of divided cells in both conditions. 
Data shown is from one single experiment where n=2 for positive control and n=1 for POL-
SAGE. Error bars represent mean ±SEM 
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Figure 4.6 - Assessing the activation ability of POL-SAGE constituents in vivo 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified, CTV-labelled naïve CL4 CD8+ T 
cells by adoptive transfer followed by PBS only, appr. 106 EID50 units of influenza virus strain 
A/PR/8/H1N1, 1 mM of POL peptide, unconjugated SAGE Trimer particles plus POL peptide or 1 
mM of POL-SAGE. 3 days later CL4 CD8+ T cells were extracted from spleens using MACS and 
stained for flow cytometry.  
(A) shows dot plots of Thy1.1 against CTV and (B) shows the CTV histogram for the POL-SAGE 
sample. 
(C) shows a bar graph comparing the percentages of divided cells in the different conditions. 
Data shown is from one single experiment where n=2. Error bars represent mean ±SEM. 
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4.5.1 Do diluted EP, POL and LEA peptides activate CD8+ Cells in vitro? 
As described in Section 4.5, both free POL peptide and POL-SAGE provoked strong 
proliferative responses from CD8+ T cells in vivo. In order to determine whether the observed 
proliferation was due to excess peptide in solution, we assessed whether or not the same effect 
is observed when EP, POL and LEA peptides were diluted in vitro. This was conducted by co-
culturing naïve, MACS-purified CD8+ T cells that had been labelled with CTV and peptide-
pulsed P815 cells (shown in Figure 4.7). The data shows that there was a statistically significant 
effect of the different peptides at different concentrations on the proliferation of CD8+ T cells 
(p≤0.001). Proliferation could be observed amongst cells cultured in the presence of POL or 
LEA peptides at stock concentration but as they were diluted by 10-fold, the percentage of 
divided cells decreased rapidly. Whilst 10-6 dilution of EP elicited division of only some cells, the 
decline in proliferation across EP concentrations was more gradual than POL or LEA dilutions 
and showed a clear distinction between the short peptide’s ability to trigger proliferation 












































Figure 4.7 - Testing diluted EP, POL and LEA peptides for CD8+ cell activation ability 
in vitro 
MACS-purified, CTV-labelled naïve CL4 CD8+ T cells were co-cultured with P815 cells which 
were previously mitomycin-treated and peptide-pulsed with either EP, POL or LEA peptide at 
different concentrations (stock: 1mM, 2-fold, 4-fold, 5-fold or 6-fold dilution of stock). Cultures 
were incubated for 48 hours at which point cells were harvested and stained using specific 
fluorochrome-labelled mAbs. 
Data is representative of 2 separate experiments with 3 technical repeats each experiment. 
Error bars represent mean ±SEM. Statistical analyses were carried out using two-way 
ANOVA followed by Bonferroni multiple comparison test. 
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4.5.2 Can diluted POL-SAGE activate CD8+ T cells in vivo? 
Since the data in Figure 4.7 suggested that dilution of EP, POL and LEA peptides in vitro 
affected the ensuing CD8+ cell proliferation, it was important to determine whether this held true 
in vivo and that dilution of the peptides would decrease the proliferative response observed. 
Thus, following adoptive transfer, mice were treated with either 1 mM or 4-fold diluted EP, POL 
or LEA peptide. CD8+ T cells were then extracted 3 days later, stained using fluorescently-
labelled mAbs and analysed (Figure 4.8).    
The data in Figure 4.8 revealed that the percentage of divided cells decreased when peptides 
were diluted. Whilst undiluted EP, POL and LEA elicited similar levels of divided cells, once 
diluted more divided cells were seen in mice treated with diluted POL or diluted LEA peptide 
than in those treated with diluted EP. This finding indicates that the results from our previous in 
vitro peptide dilution (Section 4.5.1) do not directly translate to an in vivo setting. This is likely 
due to the fact that in vivo the peptides are internalised by APCs, such as dendritic cells, 
processed and displayed to CD8+ T cells via cross presentation on MHC class I and thus drive 
their proliferation. This system is not in place in the in vitro setting where the peptides are 
presented via the MHC class I only without processing. This concurs with the fact that once 
diluted, POL and LEA initiated more proliferation than diluted EP. Since APCs prefer 
internalising longer peptides over shorter ones (139), POL (19 residues) and LEA (26 residues) 

























Figure 4.8 – Do diluted EP, POL and LEA peptides elicit proliferative responses in vivo? 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified, CTV-labelled naïve CL4 CD8+ T 
cells by adoptive transfer and subsequently received 1 mM of peptide (EP, POL or LEA) or 4-fold 
diluted peptide (EP, POL or LEA). 3 days later CL4 CD8+ T cells were extracted from spleens using 
MACS and stained for flow cytometry with fluorescently-labelled mAbs.  
Data shown is from one single experiment where n=1. 
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4.5.3 Dilution of POL peptide in vivo 
The data in Figure 4.8 showed that dilution of EP, POL and LEA decreased the CD8+ T cell 
proliferative response in vivo compared to when using their stock concentrations. In order to 
establish which concentrations of POL peptide would elicit a CD8+ T cell proliferative response 
of appropriate extend to be used in subsequent experiments, a serial dilution of POL was 
conducted in vivo to identify the most suitable concentration for use when comparing POL 
peptide with POL-SAGE. BALB/c mice received an adoptive transfer of CTV-labelled, MACS-
purified CD8+ cells and were subsequently treated with stock (200 µM), 10-2, 10-3 or 10-4 
dilutions of POL peptide. 3 days later, CD8+ cells were extracted from spleens using MACS and 
stained using specific fluorescently-labelled mAbs (Figure 4.9). Lower concentrations were used 
Figure 4.9 - Dilution of POL peptide in vivo 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified, CTV-labelled naïve CL4 CD8+ T 
cells by adoptive transfer followed by POL peptide at different concentrations (stock: 200 µM, 2-
fold, 3-fold or 4-fold dilutions) or PBS only (negative control). After 3 days CD8+ T cells were 
extracted from spleens using MACS, stained using specific mAbs for flow cytometry and analysed 
using FlowJo v10.3. 
Data shown is from one single experiment where n=1. 
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here than in previous experiments to be able to elicit an appropriate response from transferred 
CD8+ T cells and to account for the difference in the in vitro and in vivo experimental settings.  
As shown, varying magnitudes of responses were observed across different POL 
concentrations. The proliferation observed in mice treated with 4-fold diluted POL was very low 
and very similar to that of the negative control. On the other hand, POL at stock concentration 
caused CD8+ T cell proliferation so strongly that cells were close to losing the CTV dye due to 
extensive dividing. POL at 10-2 (2 µM) and 10-3 (200 nM) dilutions were the middle ground as 
these concentrations had elicited sufficient CD8+ T cell proliferation without cells dividing too 
rapidly to lose CTV. Hence, concentrations 2 µM and 200 nM were identified to be used in 
subsequent experiments for comparison with POL-SAGE. 
Based on these results, we assessed the division of CD8+ T cells in mice treated with SAGE-
POL at 2 µM or 200 nM to identify whether the proliferative response could be improved 
compared to that of POL peptide alone. To do so, BALB/c mice received adoptive transfer of 
CTV-labelled CD8+ T cells followed by treatment with either POL peptide alone or POL-SAGE, 
at one of the two concentrations (2 µM or 200 nM). After 3 days, CD8+ cells were extracted 
using MACS and stained for flow cytometry using specific mAbs (Figure 4.10). The percentage 
of CTV-negative cells is representative of proliferated cells that have undergone sufficient 
rounds of division to lose the CTV dye. Thus, at either concentration, 2 µM or 200 nM, POL-
SAGE evoked a more proliferative response than POL peptide alone as can be seen by the 
higher percentages of CTV-negative cells in samples treated with POL-SAGE. This shows that 
conjugation to the SAGE particle improved the proliferative response of CD8+ T cells compared 
to POL peptide alone.  
  































































Figure 4.10 - Comparing CD8+ T cell proliferative response of POL-SAGE to POL Peptide 
alone 
6- to 8-week old BALB/c mice received 3-5 x106 MACS-purified, CTV-labelled naïve CL4 CD8+ 
T cells by adoptive transfer followed by either POL peptide (at 2 µM or 200 nM) or POL-SAGE 
(at 2 µM or 200 nM). 3 days later CD8+ T cells were extracted from spleens using MACS, 
stained using specific mAbs for flow cytometry. (A) and (B) show flow cytometry data from mice 
treated with 2 µM POL-SAGE or 2 µM POL peptide only, respectively. (C) is a bar graph 
showing the percentages of CTV-negative cells of the different conditions. 









The presence of high levels of TILS in tumours has been correlated with good prognoses in a 
large variety of cancers (81, 83). Thus, many approaches of immunotherapeutic vaccines aim 
to generate large numbers of anti-tumour CTLs and to strengthen their effector functions to 
provide anti-tumour immunity. Often, this involves targeting DCs due to their efficiency in antigen 
uptake, processing and presentation via MHC class I molecules to CD8+ T cells (132, 133). 
Approaches to DC-based therapies include the delivery of tumour antigens in combination with 
DC stimulant (e.g. Provenge) in prostate cancer (110) and optimisation of tumour RNA-loaded 
DCs ex vivo followed by injection to the patient to initiate antigen-presentation to anti-tumour 
CTL (141). 
SAGEs are novel protein scaffolds formed of de novo coiled-coil peptides. They are composed 
of two hubs that assemble into a cage which can contain or have material attached to. Their 
components are highly interchangeable, allowing customisation of the particles for a range of 
needs. The versatility of SAGE particles provides potential for its uses in an anti-tumour context. 
Due to the hub being very flexible in what can be constructed with or enclosed within it, this 
presents the capacity to develop a vaccine with SAGEs conjugated to tumour-antigens to 
increase the number of anti-tumour CTLs by driving their proliferation. Induction of central 
tolerance hinders excessive autoimmunity but inadvertently also leads to the tolerization of anti-
tumour CTLs. This means that the few CTLs that do escape this process also exhibit low TCR 
affinity. Thus it is essential for a cancer vaccine to establish high numbers of long-lived anti-
tumour CTLs with high affinity TCRs to fight the tumour.  
In this study we investigated the ability of SAGEs to initiate proliferation of CD8+ T cells in vivo. 
Based on the work of de Haan et al (2002) (136), three different length peptides, EP, POL and 
LEA, were initially tested for their ability to initiate CD8+ T cell proliferation in vitro. Due to uptake 
and processing of the peptides prior to displaying when using irradiated Renca cells, P815 cells 
were used instead. Culturing CD8+ T cells with these MHC class I-possessing cells that had 
been pulsed with EP, POL and LEA elicited strong CD8+ T cell proliferative responses, 
confirming the peptides’ ability to be recognised by the TCR. A cathepsin cleavage site had 
been added into the LEA peptide to potentially improve peptide uptake via SAGEs by APCs. 
However, we found that the loop contained in POL was sufficient to allow targeting of SAGEs 
and elicited abundant CD8+ T cell proliferation. We found that despite some immunogenicity in 
other settings (e.g. when cultured with PBMCs; (116)), SAGEs did not prime CD8+ T cells in an 
unconjugated state. This finding ensures that proliferation observed in experiments was due to 
conjugation of peptides to the SAGE particle. Conjugation of POL peptide to SAGE molecules 
elicited higher proliferation than when using POL peptide alone in vivo, driving strong CD8+ T 
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cell responses specific to the conjugated peptide. This is an important characteristic to consider 
in the context of inducing effective anti-tumour CTLs. Since tumour-specific CTLs often exhibit 
low TCR specificity due to central tolerance, strong TCR stimulation as well as high proliferation 
of CTLs using peptide-conjugated SAGEs at the priming stage could improve targeted cytotoxic 
killing activity of CD8+ cells (75, 132).  In addition to this, the observation that conjugation of 
peptides to SAGE drastically improved the proliferative response than when free peptide only 
is injected is very significant. Vaccination of free peptide alone poses the risk of peripheral 
tolerization due to systemic distribution where T cells become unresponsive to antigen when 
exposed to high doses of it repeatedly (135), thus it is important to explore means of delivery of 
the peptide in an effective and contained manner. Investigation whether tolerization of effector 
cells occurs following SAGE injection should be strongly considered, however due to the lack 
of adjuvant needed with peptide-conjugated SAGE injections it is possible that this issue is 
reduced. The results of this study highlight the great potential of peptide-conjugated SAGEs in 
a therapeutic setting. However, it is essential to further and repeatedly test SAGEs to be able 
to draw representative conclusions. Furthermore, it is important to note that therapies to 
increase the abundance and effector functions of CTLs should be used in conjunction with 
therapies targeting the immunosuppression experienced by CTLs to prevent their switching off 
in the TME.  
To sum up, we established that conjugated SAGEs are capable of initiating sufficient 
proliferation of specific CD8+ T cells in vivo and that this response is of greater magnitude than 
when using peptide alone. Our findings demonstrate the potential of using SAGEs in anti-tumour 
immunity and whilst these initial results are very promising it is necessary to further test their 
ability to be able to develop and use SAGEs in a therapeutic setting.   
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CTLs are activated when their TCR binds tumour-antigen presented via MHC class I by APCs 
in tumour-draining lymph nodes. Activated CTLs then travel to the site of the tumour to infiltrate 
the tumour stroma in an attempt to perform their cytotoxic functions. However, in the presence 
of immunosuppressive factors such as areas of high numbers of Treg cells, high adenosine 
concentrations and anti-inflammatory factors, CTLs lose their ability to perform effector function 
and display increased CIR expression on their surface. This results in tumour tolerance where 
the tumour is not attacked and is thus able to continue to grow without interference. Tumour 
vaccinations aim to encourage the host’s own immune system to restore its anti-tumour function 
by targeting a variety of immune cells. T-cell-targeted tumour vaccines provide a viable route to 
cancer treatment as they aim to activate anti-tumour CD8+ T cells strongly to attempt restoration 
of their cytotoxic ability and prevent them from becoming exhausted. 
The work in this thesis was carried out in order to identify how adenosine influences CD8+ T 
cells towards the exhausted phenotype and how adenosine and CIR expression are related. 
We found no correlation between adenosine concentration and CIR expression on CD8+ T cell 
surface. Additionally, we found no effect of adenosine on the priming and proliferation of CD8+ 
T cells. Furthermore, we investigated how the anti-tumour response of CD8+ T cells could be 
improved and strengthened using SAGE molecules. Our data show that antigen-conjugated 
SAGEs were capable of initiating strong proliferative responses of CD8+ T cells in vivo.  
5.1 Adenosine 
Our experiments found no effect of the adenosine receptor agonist NECA on the proliferative 
ability of CD8+ T cells. Although their proliferation was unaffected, their other effector functions 
were not investigated. Thus, this should be investigated in the future by conducting tumour cell 
killing assay using CD8+ T cells that were primed in the presence of adenosine. Further, NECA 
not affecting CD8+ T cell proliferation could be due to the possible involvement of A3 adenosine 
receptors in the suppression of CD8+ T cells (43). This contribution has been debated however, 
thus it is important to establish whether signalling via A3 adenosine receptors can affect CD8+ 
T cell function. No changes were seen in the expression of CIRs when cells were activated in 
the presence or absence of NECA, suggesting no direct link between the two inhibitory factors 
in CTLs. Understanding the expression patterns of CIRs on CD8+ T cells is crucial to be able 
to use them as biomarkers of exhausted cells in cancer treatments. Co-expression of CIRs plays 
a crucial role in the limited success of checkpoint blockade therapy, as it provides resilience to 
the inhibitory pathways. Thus, it is important to characterise these co-expression patterns by 
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also assessing tumour-infiltrating lymphocytes and their CIR profiles prior to and during 
exhaustion. Our findings highlight the urgency of understanding the underlying mechanisms in 
the TME that cooperate to elicit immunosuppression to be able to develop therapies against 
them. 
5.2 SAGEs 
Our investigations found that SAGEs are capable of eliciting strong proliferative responses from 
specific CD8+ T cells. These initial results are very promising and open up further development 
of the use of SAGEs against tumours. In the context of our experiments, first and foremost it is 
essential to conduct more repeats in vivo using POL-SAGEs to increase the reliability of our 
findings. Furthermore, characterisation of CD8+ T cells activated using SAGEs is also important 
in order to assess which kind of effector cells they are. This could be done by labelling cells for 
activation, effector and memory markers to identify their characteristics using flow cytometry. 
The functionality of the primed CD8+ T cells must also be established, such as their cytotoxic 
ability in tumour killing assays. An ideal tumour vaccine would establish CTLs with TCRs 
exhibiting high affinity and avidity to tumour antigens presented to them via MHC complexes. 
Additionally, these cells would secrete high concentrations of cytotoxic factors (e.g. granzymes), 
would display molecules for T cell migration to the tumour site on their surface which would be 
maintains, such as integrins and CXCR3 (142-144), and would express high levels of 
costimulatory molecules and low levels of CIRs (132). Additionally, after proliferation of CD8+ T 
cells in vivo the numbers of DCs should be assessed to determine the longevity of the response. 
Strong activation of APCs such as DCs provides the potential to establish lasting anti-tumour 
immunity (139). Following from this, it is important to identify which APCs SAGEs target by e.g. 
fusing SAGEs with GFP or mCherry to help their localisation (115). Further, SAGE-induced 
CD8+ T cells should be examined in a tumour model to compare tumour growth in mice given 
adoptive transfer with or without SAGE. Or alternatively, mice should be inoculated with SAGEs 
prior to challenging the system with tumour cells to assess the possibility of using SAGEs in a 
prophylactic manner.  
5.3 Therapies 
Our findings showed that SAGEs can be used to initiate CD8+ T cell proliferative responses in 
vivo. This is very encouraging for the potential use of SAGEs as T-cell-inducing vaccines, either 
in the treatment of tumours or preventatively (132). By establishing a strong TCR signal during 
CTL activation, SAGEs could help reinstate the anti-tumour functions of CTLs (75, 132). It is 
important to consider that despite the CTL activation ability of SAGEs, tolerization is still 
possible. However due to the lack of adjuvant needed for potency of SAGE, this is unlikely. 
Furthermore, a large limitation in the development of tumour vaccines is the identification of 
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tumour antigens. Thus, this highlights the importance of identifying antigens consistently 
expressed on and specific to tumours to be able to efficiently target therapies against them. 
Based on the success of combining different immunotherapeutic approaches, such as the 
combination of Nivolumab with chemotherapy, it is important to not see current therapies as 
different entities but instead consider their synergism together to achieve lasting anti-tumour 
immunity. 
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Figure 6.1 - Proposed model of suppression of CL4 CD8+ T cells by 
adenosine production by tumour infiltrating Treg cells 
Within the TDLN, Treg cells express lower levels of ectoenzymes CD39 and 5’nucleotidase. 
CD39 catalyses the breakdown of ATP into ADP as well as ADP into AMP. AMP is in turn broken 
down to adenosine by 5’nucleotidase. CL4 CD8+ T cells express adenosine receptor A2AR. 
However, within the tumour, high levels of CD39 and 5’nucleotidase result in elevated 
production and accumulation of adenosine, which binds to A2AR receptors on CL4 CD8+ T cells 
and causes suppression of anti-tumour function. 
 
 
Figure 6.1 - Proposed model of suppression of CL4 CD8+ T cells by adenosine 
production by tumour-infiltrating Treg cells 
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Figure 6.2 - Gating strategy for CL4 mouse typing 
Blood samples were collected from the tail veins of CL4 mice. Following erythrocyte lysis, blood 
was stained using fluorescently-labelled mAbs specific for CD8α and Vβ8.1 to analyse CL4 TCR 
gene expression. CL4 mice (A) have higher percentages of CD8α+Vß8.1+ cells (Q2) than CL4-
negative mice (B). 
  
Figure 6.2 - Gating Strategy for CL4 mouse typing 
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Figure 6.3 - Enrichment Purity of MACS 
Positive enrichment of CL4 CD8+ T cells was performed in experiments as indicated. After 
isolation of cells from spleens, CD8+ T cells were bound to anti-CD8-labelled magnetic 
microbeads and purified using magnetic-activated sorting. This involves the application of the 
cells through a magnetic column in a magnetic field, separating cells of interest out of 
suspension by positive selection which are subsequently flushed out. Enrichment Purity of this 
method was routinely ~95% (Q2). 
 
  
Figure 6.3 - Enrichment Purity of MACS 
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Antibody Fluorochrome Dilution Source Clone  
CD8α FITC 1 in 100 Biolegend 53-6.7 
CD8β PE-Cy7 1 in 200 Biolegend 53-5.8 
LAG3 PE-Cy7 1 in 200 eBiosciences C9B7W 
PD1 BV785 1 in 200 Biolegend 29F.1A12 
THY1.1 PerCP Cy5.5 1 in 100 Biolegend OX-7 
TIGIT APC 1 in 100 Biolegend IG9 
TIM3 BV605 1 in 100 Biolegend RMT3-23 
TIM3 PE 1 in 100 Biolegend B8.2C12 
Vβ8.1 FITC 1 in 200 eBiosciences KJ16-133 
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Figure 6.4 - Gating CD8+ T cell Proliferation 
1x106 MACS-purified CL4 CD8+ T cells were labelled with CTV and subsequently activated 
using either anti-CD3 and anti-CD28 antibodies or pulsed splenocyte reaction (PSR). Cells 
were harvested after 72 hours of culture and prepared for flow cytometry analysis using 
fluorochrome-conjugated anti-CD8 mAbs.  
CTV binds free amines on and within the cell so that as cells undergo cell division, the dye is 
split between the daughter cells. Thus, undivided cells are more fluorescent than cells having 
divided, with fluorescence decreasing the more cells have proliferated. This generates several 
populations of cells of different degrees of fluorescence depending on the number of divisions 
they have undergone. 
  
Figure 6.4 - Gating CD8+ T cell Proliferation 
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